Chronic_Obstructive_Pulmonary_Disease

🏷

Classifications

Harrison's Part

◆

Subtypes

2

Chronic Bronchitis

Inflammation of the bronchial tubes leading to increased mucus production and chronic cough.

Show evidence (3 references)

PMID:23204254 SUPPORT

"Chronic bronchitis (CB) is a common but variable phenomenon in chronic obstructive pulmonary disease (COPD)."

The article clearly states that Chronic Bronchitis (CB) is a subtype of COPD, characterized by inflammation of the bronchial tubes leading to increased mucus production and chronic cough.

PMID:27264777 SUPPORT

"Chronic obstructive pulmonary disease (COPD) is an umbrella term that covers many clinical subtypes with clearly different pulmonary and extra-pulmonary characteristics."

The article supports that COPD has multiple subtypes with differing characteristics, encompassing conditions like Chronic Bronchitis.

PMID:22753831 SUPPORT

"Chronic cough and sputum production: a clinical COPD phenotype?"

The article discusses the phenotype of COPD which includes chronic cough and sputum production, indicative of conditions like Chronic Bronchitis.

Emphysema

Damage to the alveoli resulting in shortness of breath and reduced surface area for gas exchange.

Show evidence (2 references)

PMID:33926668 SUPPORT

"Chronic obstructive pulmonary usually is subcategorized into 2 groups: chronic bronchitis and emphysema."

This reference reiterates the point that emphysema is a recognized subtype of COPD.

PMID:21178627 SUPPORT

"Latest studies further support the association of emphysema and COPD with coal dust exposure."

This confirms that emphysema is considered a subtype of COPD, further supporting the statement.

C

Comorbidities

Asthma <-> Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease <-> Fibromyalgia

◈

Mechanistic Hypotheses

1

Emerging Cuproptosis Metabolic-Immune Cell Death Axis

emerging_cuproptosis_metabolic_immune_axis EMERGING

Evidence balance 2 support

A 2026 review proposes that cuproptosis — copper-dependent regulated cell death driven by mitochondrial proteotoxic stress — is not a bystander consequence of COPD but an amplifier of it, running as a self-sustaining loop: smoke-induced disruption of pulmonary copper homeostasis permits cuproptotic death of alveolar epithelium and M2 macrophages, the resulting DAMP release drives neutrophilic inflammation, and that inflammation further impairs copper handling in surviving cells. The grouping exists to keep the two edges of this loop distinguishable in the pathograph from the entry's established protease/antiprotease and oxidative-stress mechanisms. Its central vulnerability claim — that OXPHOS-dependent cells are the preferential targets — is stated by the authors as a prediction, and the review is a synthesis rather than a report of primary human COPD data.

Contrast with the entry's other cell-death and inflammation nodes, which rest on primary human airway data. No competing hypothesis grouping is declared, because the established mechanisms in this entry are not framed as alternatives to this one — the axis is proposed as superimposed on them.

Pathograph links

Chronic Inflammation -> Cuproptosis-Driven Cell Death DIRECT Return arm of the proposed metabolic-immune axis: the inflammatory milieu impairs copper handling in cells that survived the first round of cuproptosis, sensitizing them to a further round. Modelled as an edge rather than left in prose so the cycle the review describes is visible in the pathograph, and grouped under the emerging hypothesis because the loop is proposed rather than demonstrated.

Cuproptosis-Driven Cell Death -> Chronic Inflammation Cuproptotic DAMP release from dying epithelial cells and M2 macrophages amplifies neutrophilic recruitment and pro-inflammatory macrophage polarization, creating a vicious cycle of inflammation.

Show evidence (2 references)

PMID:42604614 SUPPORT Other

"In this review, we advance the hypothesis that cuproptosis functions not merely as a passive consequence but as a critical amplifier within a self-sustaining "Metabolic-Immune Cell Death Axis" that drives disease chronicity and progression."

The authors frame the axis as a hypothesis in their own words, which is what fixes this grouping's status as EMERGING rather than CANONICAL.

PMID:42604614 SUPPORT Other

"while explicitly distinguishing established evidence from speculative hypotheses"

Carried deliberately: the review itself marks part of its content as speculative, which bounds how far the edges in this group can be read.

?

Discussions and Knowledge Gaps

2

Does restoring NAD+-dependent SIRT1 deacetylase activity causally reduce neutrophilic airway inflammation and alveolar epithelial senescence in COPD, and can SIRT1 activators overcome their pharmacokinetic limitations and be paired with biomarker-guided patient stratification to translate this protection into therapy?

KNOWLEDGE GAP OPEN gap_copd_sirt1_senescence_neutrophilic_translation

Attached to

pathophysiology#Chronic Inflammation pathophysiology#Cellular Senescence

SIRT1 is reported to protect against COPD by inhibiting NF-kB and STAT3, activating Nrf2 and FOXO3, and suppressing TGF-beta/Smad, thereby reducing neutrophilic inflammation, mitigating alveolar epithelial senescence, and helping restore protease/antiprotease balance. These protective effects are mechanistically distinct from SIRT1's role in asthma, where it chiefly attenuates type 2 inflammation and mucus hypersecretion, so the disease context appears to determine which downstream program SIRT1 restrains. The COPD entry captures chronic neutrophilic inflammation and cellular senescence as separate nodes but does not resolve whether SIRT1 activity is causally required to limit each one, nor in which cell type (alveolar epithelium, neutrophil, macrophage) the protective signaling resides. Translation is further limited by the poor pharmacokinetics of current SIRT1 activators and by the absence of biomarkers to select responders. Resolving the cell-type-specific basis of these context-dependent effects and the pharmacokinetic and stratification barriers would convert SIRT1 from a broadly cytoprotective pathway into a stratified COPD therapeutic target.

Seeded from PMID:42181267 — Emerging role of SIRT1 in asthma and COPD from molecular mechanisms to translational therapy

Does cuproptosis actually occur in human COPD airway tissue, and are OXPHOS-dependent cells (alveolar type II epithelium, M2 macrophages) the preferentially vulnerable populations the metabolic-immune axis model predicts?

KNOWLEDGE GAP OPEN gap_copd_cuproptosis_direct_human_evidence

Attached to

pathophysiology#Cuproptosis-Driven Cell Death

The entire cuproptosis node in this entry rests on one review, and that review's own roadmap puts direct human evidence first among what is missing. The cell-type vulnerability claim is stated as a prediction from metabolic dependency rather than as an observation, so the node's cell-type bindings (CL:0002063, CL:0000890) record what the model expects rather than what has been measured in patient tissue. Resolving this would need demonstration of the cuproptosis signature — copper-dependent aggregation of lipoylated mitochondrial proteins and Fe-S cluster loss — in COPD lung with the affected cells identified, which would move the emerging_cuproptosis_metabolic_immune_axis grouping toward established status or refute it. The related therapeutic question is separately blocked: every proposed copper chelator, ionophore, nanoplatform and PROTAC sensitizer is preclinical, so none is curated under treatments.

Seeded from PMID:42604614 alongside the cuproptosis node added in #10119.

Show evidence (2 references)

PMID:42604614 SUPPORT Other

"prioritizing direct human evidence, biomarker validation, and rigorous preclinical safety studies"

The review's own research roadmap names direct human evidence as the first outstanding requirement, which is the gap this entry records.

PMID:42604614 SUPPORT Other

"we emphasize that all these approaches remain at preclinical or early exploratory stages, with no clinical trials yet conducted in COPD"

Establishes why the surveyed copper-directed therapeutics are recorded here rather than curated as treatments.

⚙

Pathophysiology

11

Airflow Limitation

Obstruction of airflow due to inflammation, mucus build-up, and remodeling of the airways.

Epithelial Cell CL:0000066

inflammatory response GO:0006954 airway remodeling

bronchus UBERON:0002185 small airway

Downstream

Progressive Respiratory Impairment Chronic airway inflammation and remodeling lead to progressive airflow obstruction and respiratory decline.

Show evidence (3 references)

PMID:23204254 SUPPORT

"CB is caused by overproduction and hypersecretion of mucus by goblet cells, which leads to worsening airflow obstruction by luminal obstruction of small airways, epithelial remodeling, and alteration of airway surface tension predisposing to collapse"

This study describes how mucus build-up and epithelial remodeling lead to airflow obstruction in COPD.

PMID:36108172 SUPPORT

"Phenotypic alterations in the lung epithelium have been widely implicated in chronic obstructive pulmonary disease (COPD) pathogenesis, but the precise mechanisms orchestrating this persistent inflammatory process remain unknown."

This study notes the involvement of epithelial cells in COPD but states that mechanisms remain unknown, partially supporting the role of epithelial cells in airflow obstruction.

PMID:38625125 SUPPORT

"Chronic exposure to environmental hazards causes airway epithelial dysfunction, primarily impaired physical barriers, immune dysfunction, and repair or regeneration. Impairment of airway epithelial function subsequently leads to exaggerated airway inflammation and remodeling, the main features..."

This study supports the statement by highlighting the role of epithelial dysfunction, inflammation, and remodeling in COPD pathophysiology.

Chronic Inflammation

Persistent irritation from inhaled substances like cigarette smoke leads to airway and alveolar inflammation.

Emerging Cuproptosis Metabolic-Immune Cell Death Axis

Neutrophil CL:0000775 Macrophage CL:0000235 T-lymphocyte CL:0000084

inflammatory response GO:0006954 neutrophil degranulation GO:0043312

bronchus UBERON:0002185 alveolus of lung UBERON:0002299

Downstream

Cuproptosis-Driven Cell Death Return arm of the proposed metabolic-immune axis: the inflammatory milieu impairs copper handling in cells that survived the first round of cuproptosis, sensitizing them to a further round. Modelled as an edge rather than left in prose so the cycle the review describes is visible in the pathograph, and grouped under the emerging hypothesis because the loop is proposed rather than demonstrated.

Show evidence (5 references)

PMID:17305517 SUPPORT

"Neutrophils and macrophages have been implicated in this process; they release proteolytic enzymes and generate oxidants, which cause tissue damage, as well as cytokines and chemokines, which can potentiate inflammation and trigger an immune response."

The literature describes the involvement of neutrophils, macrophages, and T-lymphocytes in the inflammatory process associated with COPD, supporting the notion of persistent irritation and chronic inflammation.

PMID:24507838 SUPPORT

"This inflammation is characterized by increased numbers of alveolar macrophages, neutrophils, and T lymphocytes, which are recruited from the circulation."

This article further substantiates the involvement of these cell types (neutrophils, macrophages, and T-lymphocytes) in the pathophysiology of COPD, linking them to chronic inflammation.

PMID:38035712 SUPPORT

"In this study, we found that neutrophilic phenotype (NP, 58.0%) was the most common airway inflammation phenotype in patients with COPD, followed by mixed granulocytic phenotype (MGP, 32.6%)."

The study indicates that neutrophils are predominant in COPD, supporting the statement about chronic inflammation.

+ 2 more references

Airway Remodeling

Structural changes in the airway due to chronic inflammation, including fibrosis and increased airway thickness.

Smooth Muscle Cell CL:0000192

extracellular matrix organization GO:0030198 fibrosis

bronchus UBERON:0002185 small airway

Experimental models

Patient-derived epithelial-endothelial COPD airway-on-a-chip ORGAN ON CHIP The chip supports full mucociliary differentiation with ciliary beating and permits compartment-specific RNA extraction, giving a route to measure epithelial differentiation state and epithelial-endothelial crosstalk in COPD cells.

Show evidence (3 references)

PMID:20500603 SUPPORT

"Moreover, airway remodelling occurs not only in asthma but also in several pulmonary disorders such as chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis and systemic sclerosis."

The statement aligns with the mentioned literature which notes airway remodeling as part of chronic obstructive pulmonary disease.

PMID:30257694 SUPPORT

"Multiple dysfunctions of ASM contribute to modulating airway responses to stimuli, remodeling, and fibrosis, as well as influence the compliance of lungs."

The statement is supported as this literature highlights the role of airway smooth muscle cells in airway remodeling and fibrosis in COPD.

PMID:15347849 SUPPORT

"Increases in airway smooth muscle mass occur in large airways of severe asthmatics and in small airways of patients with COPD."

The literature supports the statement by confirming the involvement of smooth muscle cells and structural changes in the airways in COPD.

Alveolar Destruction

Breakdown of alveolar walls, leading to reduced surface area for gas exchange and loss of lung elasticity.

Alveolar Macrophage CL:0000583

proteolysis GO:0006508 extracellular matrix organization GO:0030198

alveolus of lung UBERON:0002299 lung parenchyma UBERON:0008946

Experimental models

Open-top vascularized alveolus-on-chip whole cigarette smoke model ORGAN ON CHIP Repeated whole cigarette smoke exposure disintegrated the alveolar microvascular network. The informative control is that the epithelium itself stayed intact and that vascular networks exposed to smoke without an overlying epithelium were undamaged, which locates the vascular injury downstream of an epithelial signal rather than in direct smoke contact. This supports the vascular limb of the alveolar destruction in emphysema.

Show evidence (4 references)

PMID:11993785 SUPPORT

"In the lung parenchyma, emphysema defined as alveolar destruction and airspace enlargement is present."

While the reference supports alveolar destruction as part of COPD's pathophysiology, it does not mention alveolar macrophages specifically.

PMID:29433833 SUPPORT

"In inflammatory lung diseases such as chronic obstructive pulmonary disease (COPD), despite their increased numbers, macrophages demonstrate significantly reduced phagocytic capacity of bacteria and apoptotic cells."

The macrophages' role in the pathophysiology of COPD is discussed, focusing on their reduced phagocytic capacity rather than direct alveolar destruction.

PMID:32493486 SUPPORT

"External insults like smoke and pollution can disturb surfactant homeostasis and result in either surfactant insufficiency or accumulation. But disruption of surfactant homeostasis is also observed in many chronic adult diseases, including chronic obstructive pulmonary disease (COPD)."

The role of alveolar macrophages (responsible for the degradation of surfactant) in the development of COPD is mentioned, but no direct link to alveolar destruction.

+ 1 more reference

Oxidative Stress and Mitochondrial Dysfunction

Cigarette smoke and pollutants trigger mitochondrial ROS production, impaired mitophagy, and reduced antioxidant defenses, amplifying inflammation.

airway epithelial cell CL:0002368 Alveolar Macrophage CL:0000583

response to oxidative stress GO:0006979 mitochondrion organization GO:0007005 mitophagy GO:0000422

bronchus UBERON:0002185 alveolus of lung UBERON:0002299

Experimental models

Open-top vascularized alveolus-on-chip whole cigarette smoke model ORGAN ON CHIP The platform delivers a controlled, repeated airborne whole-smoke exposure to human alveolar cells and supports perfusion of monocytes through the vascular network, providing a route to measure smoke-induced injury and immune recruitment together.

Downstream

Protease-Antiprotease Imbalance (MMP-2/TIMP-2 Axis) Oxidative stress activates NF-κB, MAPK, and AP-1 signaling, which upregulates MMP-2 and dysregulates TIMP-2 — the disorder-specific form of the module's Oxidant and Inflammatory Trigger edge into Protease-Antiprotease Imbalance.

Show evidence (1 reference)

PMID:42181267 SUPPORT Other

"Shared benefits include mitigation of oxidative stress, mitochondrial dysfunction, and extracellular matrix remodeling"

This review identifies mitigation of oxidative stress as a shared benefit of SIRT1 activation in obstructive airway disease, supporting SIRT1's role as a regulator of oxidative stress in COPD.

Mucus Hypersecretion

Upregulation of MUC5AC and MUC5B, goblet cell hyperplasia, and impaired mucociliary clearance contribute to mucus plugging.

goblet cell CL:0000160 club cell CL:0000158

mucus secretion GO:0070254 cilium movement GO:0003341

bronchus UBERON:0002185 small airway

Experimental models

Patient-derived epithelial-endothelial COPD airway-on-a-chip ORGAN ON CHIP Chips built from COPD patient cells showed enhanced mucus production relative to healthy-donor chips under identical conditions, reproducing a cardinal COPD phenotype without any exposure being applied.

NLRP3 Inflammasome Activation

Mitochondrial ROS and particulate exposures activate NLRP3 inflammasome, leading to caspase-1 activation and IL-1β/IL-18 release.

Macrophage CL:0000235 airway epithelial cell CL:0002368

inflammatory response GO:0006954

NLRP3 inflammasome complex GO:0072559

bronchus UBERON:0002185 alveolus of lung UBERON:0002299

Cellular Senescence

Senescent epithelial, fibroblast, and immune cells exhibit senescence-associated secretory phenotype (SASP), promoting chronic inflammation and remodeling.

airway epithelial cell CL:0002368 fibroblast CL:0000057

cellular senescence GO:0090398 inflammatory response GO:0006954

lung UBERON:0002048

SIRT1-Mediated NAD+ Signaling and Protective Deacetylation

SIRT1 (Sirtuin 1), an NAD+-dependent deacetylase, exerts protective effects in COPD by inhibiting pro-inflammatory signaling pathways (NF-κB, STAT3) while activating stress-response transcription factors (Nrf2, FOXO3) and suppressing pro-fibrotic TGF-β/Smad signaling. In COPD, SIRT1 reduces neutrophilic inflammation, mitigates alveolar senescence, and helps restore protease/antiprotease balance. SIRT1 also mitigates oxidative stress and mitochondrial dysfunction.

Neutrophil CL:0000775 Airway Epithelial Cell CL:0002368 Alveolar Macrophage CL:0000583

SIRT1 hgnc:14929 NFKB1 hgnc:7794 STAT3 hgnc:11364 NFE2L2 hgnc:7782 FOXO3 hgnc:3821 TGFB1 hgnc:11766

protein deacetylation GO:0006476 response to oxidative stress GO:0006979 transcriptional regulation GO:0006355 negative regulation of inflammatory response GO:0050728

Downstream

Chronic Inflammation SIRT1-mediated deacetylation inhibits NF-κB and STAT3 signaling, reducing neutrophilic recruitment and pro-inflammatory cytokine production.

Cellular Senescence SIRT1 suppresses senescence-associated secretory phenotype (SASP) and promotes cell viability in epithelial and immune cells.

Alveolar Destruction SIRT1 suppresses TGF-β/Smad pro-fibrotic signaling and restores protease/antiprotease balance through Nrf2-mediated antioxidant responses.

Oxidative Stress and Mitochondrial Dysfunction SIRT1 activation of Nrf2 and FOXO3 enhances antioxidant defenses and mitochondrial homeostasis, reducing ROS-driven inflammasome activation.

Show evidence (3 references)

PMID:42181267 SUPPORT Other

"SIRT1, an NAD+-dependent deacetylase, exerting protective effects by inhibiting NF-κB and STAT3, activating Nrf2 and FOXO3, and suppressing TGF-β/Smad."

This review identifies the key molecular mechanisms through which SIRT1 exerts protective effects in COPD by targeting multiple pro-inflammatory and pro-fibrotic pathways.

PMID:42181267 SUPPORT Other

"in COPD, it reduces neutrophilic inflammation, alveolar senescence, and protease/antiprotease imbalance."

This review explicitly describes SIRT1's protective effects specific to COPD pathophysiology, directly addressing three key pathological mechanisms.

PMID:42181267 SUPPORT Other

"Shared benefits include mitigation of oxidative stress, mitochondrial dysfunction, and extracellular matrix remodeling."

Describes SIRT1's shared protective mechanisms across multiple pathophysiological domains relevant to asthma and COPD.

Protease-Antiprotease Imbalance (MMP-2/TIMP-2 Axis)

Oxidative stress dysregulates the matrix metalloproteinase-2 (MMP-2) to tissue inhibitor of metalloproteinase-2 (TIMP-2) ratio, tipping the balance toward unopposed proteolysis of the alveolar extracellular matrix. Cigarette smoke and particulate matter exposure activate inflammatory signaling (NF-κB, MAPK, AP-1) that upregulates MMP-2 expression and suppresses TIMP-2 activity, resulting in enhanced degradation of lung elastic fibers and collagen. Genetic polymorphisms in MMP-2 and TIMP-2 influence individual susceptibility and disease severity.

Neutrophil CL:0000775 Alveolar Macrophage CL:0000583

Proteolysis GO:0006508 ↑ INCREASED Extracellular Matrix Disassembly GO:0022617 ↑ INCREASED Response to Oxidative Stress GO:0006979

Downstream

Alveolar Destruction Unopposed MMP-2 proteolysis degrades the elastic fiber network and collagen of the alveolar wall, the conserved module edge from Protease-Antiprotease Imbalance to Alveolar ECM and Elastin Destruction.

Show evidence (2 references)

PMID:42556749 SUPPORT Other

"oxidative stress-mediated activation of inflammatory signaling pathways such as nuclear factor-κB (NF-κB), mitogen-activated protein kinase (MAPK), and activator protein-1 (AP-1). These pathways contribute to the upregulation of MMP-2 expression and dysregulation of TIMP-2 activity, resulting in..."

This review establishes oxidative stress-driven MMP-2 upregulation and TIMP-2 dysregulation as central to protease-antiprotease imbalance in COPD pathogenesis and alveolar destruction.

PMID:42556749 SUPPORT Other

"genetic polymorphisms in MMP-2 and TIMP-2 genes that may influence susceptibility to COPD and disease severity across different populations."

Identifies genetic variation in the MMP-2/TIMP-2 axis as a determinant of COPD susceptibility and disease phenotype across populations.

Cuproptosis-Driven Cell Death

Proposed mechanism, advanced explicitly as a hypothesis by a 2026 review and not yet demonstrated directly in human COPD tissue. Cigarette smoke disrupts pulmonary copper homeostasis, creating a microenvironment permissive for cuproptosis — a copper-dependent regulated cell death driven by mitochondrial proteotoxic stress. Cuproptotic death of structural cells (alveolar epithelium and anti-inflammatory M2 macrophages) releases damage-associated molecular patterns (DAMPs) that fuel neutrophilic inflammation and pro-inflammatory macrophage polarization; that inflammatory milieu in turn impairs copper handling in surviving cells, which is the loop the review calls a self-sustaining metabolic-immune axis. Cellular metabolic dependency is proposed as the determinant of vulnerability: cells reliant on oxidative phosphorylation (alveolar type II epithelial cells, M2 macrophages) are predicted, not shown, to be exquisitely vulnerable.

Emerging Cuproptosis Metabolic-Immune Cell Death Axis

alveolar type II cell CL:0002063 anti-inflammatory M2 macrophage CL:0000890

copper homeostasis GO:0055070 ↕ DYSREGULATED stress response to copper ion GO:1990169 cuproptosis GO:0160119 mitochondrial proteotoxic stress GO:0141164 oxidative phosphorylation GO:0006119 inflammatory response GO:0006954 ↑ INCREASED

alveolus of lung UBERON:0002299 bronchus UBERON:0002185

Downstream

Chronic Inflammation Cuproptotic DAMP release from dying epithelial cells and M2 macrophages amplifies neutrophilic recruitment and pro-inflammatory macrophage polarization, creating a vicious cycle of inflammation.

Show evidence (5 references)

PMID:42604614 SUPPORT Other

"cuproptosis functions not merely as a passive consequence but as a critical amplifier within a self-sustaining "Metabolic-Immune Cell Death Axis" that drives disease chronicity and progression"

Review proposes cuproptosis as a novel regulatory mechanism in COPD amplifying disease progression.

PMID:42604614 SUPPORT Other

"cigarette smoke actively disrupts pulmonary copper homeostasis"

Establishes cigarette smoke as the trigger for copper dysregulation in COPD pathogenesis.

PMID:42604614 SUPPORT Other

"cuproptotic death of structural cells releases immunogenic damage-associated molecular patterns (DAMPs) that fuel neutrophilic inflammation and pro-inflammatory macrophage polarization"

Describes DAMP-mediated amplification of inflammation as a consequence of cuproptotic cell death.

+ 2 more references

⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.

Referential integrity issues (1):

Target 'Progressive Respiratory Impairment' (from 'Airflow Limitation') not found in named elements

●

Phenotypes

11

Musculoskeletal 1

Barrel Chest OCCASIONAL Barrel-shaped chest HP:0001552

Due to hyperinflation of the lungs

Show evidence (3 references)

PMID:25159007 SUPPORT

"Lung hyperinflation is highly prevalent in patients with chronic obstructive pulmonary disease and occurs across the continuum of the disease."

The reference supports the association of lung hyperinflation with COPD but does not specifically mention 'Barrel Chest' or its frequency.

PMID:34972922 SUPPORT

"Attempts to connect the products of the analysis of the EBC with the clinical manifestations of COPD such as dyspnea are scarce."

The reference discusses the clinical manifestations of COPD but does not specifically mention 'Barrel Chest' or its frequency.

PMID:23204254 NO_EVIDENCE

"Chronic bronchitis (CB) is a common but variable phenomenon in chronic obstructive pulmonary disease (COPD)."

The reference discusses chronic bronchitis in COPD but does not mention 'Barrel Chest' or its frequency.

Respiratory 7

Dyspnea VERY_FREQUENT HP:0002094

Sequelae: Exercise Intolerance

Show evidence (3 references)

PMID:28277858 SUPPORT

"Indeed, it is an important symptom in chronic obstructive pulmonary disease (COPD), where it is associated with limited physical activity, increased anxiety and depression, decreased health-related quality of life (HRQoL), and reduced survival."

The literature supports that dyspnea is a common symptom in COPD and is frequently observed in patients, confirming its categorization as a respiratory phenotype with diagnostic importance.

PMID:35698999 SUPPORT

"Dyspnoea and pain are symptoms of chronic obstructive pulmonary disease (COPD)... The pooled prevalence of pain and dyspnoea was 44% (95% confidence interval (CI) 35%-52%) and 91% (95% CI 87%-94%) respectively."

This study highlights the high prevalence of dyspnea in patients with COPD, further supporting its status as a very frequent respiratory phenotype.

PMID:34972922 SUPPORT

"Up to date research has shown a positive correlation between the elevated levels of some markers of EBC such as H2O2 and 8-isoprostane and dyspnea, while others present ambiguous results"

The correlation between dyspnea and COPD is reinforced by the positive association found with certain markers in exhaled breath condensate.

Chronic Cough VERY_FREQUENT HP:0034315

Often productive of mucus

Show evidence (2 references)

PMID:29881269 SUPPORT

"Compared with patients without chronic cough, those with chronic cough exhibited a lower forced expiratory volume in 1 second (% predicted) and diffusing capacity of the lungs for carbon monoxide (% predicted), more frequent AECOPD, more severe dyspnea, and worse QoL."

The study identifies chronic cough as a common and significant phenotype in COPD patients, indicating its very frequent occurrence and diagnostic importance.

PMID:31740261 SUPPORT

"COPD is now widely accepted as a heterogeneous condition with multiple phenotypes and endotypes. This review will discuss the old and new concepts for the different types of COPD phenotypes."

The statement mentions the heterogeneity of COPD with multiple phenotypes, which could include phenotypes like chronic cough.

Sputum Production VERY_FREQUENT Increased sputum production HP:0033709

Mucus is often difficult to expectorate

Show evidence (2 references)

PMID:22753831 SUPPORT

"Chronic cough and sputum production: a clinical COPD phenotype?"

The title of the article itself suggests that sputum production is recognized as a phenotype of COPD.

PMID:23204254 SUPPORT

"Chronic bronchitis (CB) is a common but variable phenomenon in chronic obstructive pulmonary disease (COPD)."

Chronic bronchitis, which involves overproduction and hypersecretion of mucus, is described as a common phenomenon in COPD, indicating sputum production is a frequent COPD phenotype.

Wheezing FREQUENT HP:0030828

Due to airflow obstruction

Show evidence (3 references)

PMID:33302722 SUPPORT

"The clinical symptoms of this disease include progressive dyspnea, cough, expectoration, and wheezing, among others."

The abstract mentions wheezing as one of the clinical symptoms of Chronic Obstructive Pulmonary Disease (COPD).

PMID:11963614 SUPPORT

"Remember, all that wheezes is not asthma; therefore, providers in this case had to determine if the patient was suffering something such as anaphylaxis, asthma, bronchitis, pneumonia or even congestive heart failure (CHF)."

The abstract indicates that wheezing can be a symptom of various conditions, including COPD-related bronchospasm.

PMID:2404712 SUPPORT

"Increased airways reactivity is present in 15 to 70 percent of patients with chronic airflow obstruction."

The abstract discusses increased airway reactivity, which is related to wheezing, in patients with chronic airflow obstruction, including COPD.

Respiratory Failure OCCASIONAL HP:0002878

Sequelae: Hypoxemia Hypercapnia

Show evidence (2 references)

PMID:14621114 REFUTE

"Respiratory failure is still an important complication of chronic obstructive pulmonary disease (COPD) and hospitalisation with an acute episode being a poor prognostic marker."

The reference indicates that respiratory failure is an important and common complication of COPD, not an occasional one.

PMID:38692758 REFUTE

"Hypoventilation is a complication that is not uncommon in chronic obstructive pulmonary disease and calls for both medical treatment of the underlying disease and, frequently, noninvasive ventilation either during exacerbations requiring hospitalization or in a chronic state in the patient at home."

The reference suggests that hypoventilation, which can lead to respiratory failure, is not uncommon in COPD.

Hypoxemia FREQUENT HP:0012418

Hypercapnia FREQUENT HP:0012416

Constitutional 2

Fatigue FREQUENT HP:0012378

Show evidence (3 references)

PMID:33998496 SUPPORT

"Fatigue: A neglected symptom of COPD."

The title itself indicates that fatigue is a recognized symptom of COPD.

PMID:31729154 SUPPORT

"Fatigue is an important yet ignored symptom of chronic obstructive pulmonary disease (COPD)."

This reference acknowledges fatigue as an important symptom of COPD, supporting its frequent occurrence.

PMID:24874124 SUPPORT

"Symptoms in COPD do not solely arise from the degree of airflow obstruction as exercise limitation is compounded by the specific secondary manifestations of the disease including skeletal muscle impairment, osteoporosis, mood disturbance, anemia, and hormonal imbalance."

While this reference does not mention fatigue explicitly, it discusses systemic manifestations of COPD, implying the systemic nature of the disease.

Exercise Intolerance FREQUENT HP:0003546

Growth 1

Weight Loss OCCASIONAL HP:0001824

More common in advanced disease

Show evidence (3 references)

PMID:12406664 SUPPORT

"Weight loss occurs frequently in patients with chronic obstructive pulmonary disease (COPD)."

The literature states that weight loss is a common phenomenon in COPD patients, which supports the statement that weight loss is a systemic issue in COPD, more common in advanced disease.

PMID:18415812 SUPPORT

"These include unintentional weight loss, skeletal muscle dysfunction, an increased risk of cardiovascular disease, osteoporosis, and depression, among others."

This reference mentions unintentional weight loss as one of the systemic effects of COPD, supporting the statement.

PMID:36922031 SUPPORT

"COPD patients with psychological (high anxiety and depression) and cachectic (underweight and osteoporotic) comorbidity have higher mortality and exacerbate more."

The mention of cachexia (underweight) as a comorbidity in COPD patients aligns with the statement about weight loss being more common in advanced disease.

🧬

Genetic Associations

7

SERPINA1 (Alpha-1 antitrypsin deficiency is the most common genetic cause of COPD.)

Gene: SERPINA1 hgnc:8941

Show evidence (3 references)

PMID:32800189 SUPPORT

"Alpha-1 antitrypsin deficiency (AATD) was the first genetic risk factor for chronic obstructive pulmonary disease (COPD) described."

The abstract clearly mentions that AATD is a genetic risk factor for COPD, supporting the statement.

PMID:35104244 SUPPORT

"Alpha-1 antitrypsin deficiency (AATD) is the most common genetic cause and risk factor for chronic obstructive pulmonary disease."

The text directly supports the statement by identifying AATD as a common genetic cause and risk factor for COPD.

PMID:36630963 SUPPORT

"Genetic variation in alpha-1 antitrypsin (AAT) causes AAT deficiency (AATD) through liver aggregation-associated gain-of-toxic pathology and/or insufficient AAT activity in the lung manifesting as chronic obstructive pulmonary disease (COPD)."

The abstract highlights that genetic variation in AAT leading to AATD manifests as COPD, thus supporting the statement.

MMP12 (Matrix metalloproteinase-12 contributes to emphysema development.)

Gene: MMP12 hgnc:7158

NLRP3 (Inflammasome activation contributes to chronic inflammation.)

Gene: NLRP3 hgnc:16400

TNF (Tumor necrosis factor mediates systemic and airway inflammation.)

Gene: TNF hgnc:11892

IL1B (Interleukin-1 beta drives inflammatory signaling.)

Gene: IL1B hgnc:5992

IL6 (Interleukin-6 contributes to systemic inflammation.)

Gene: IL6 hgnc:6018

NFE2L2 (Nrf2 transcription factor regulates antioxidant defense.)

Gene: NFE2L2 hgnc:7782

💊

Medical Actions

11

Smoking Cessation

Action: behavioral counseling Ontology label: Behavioral Counseling NCIT:C181743

Stopping smoking to slow disease progression and improve outcomes.

Show evidence (4 references)

PMID:25496790 SUPPORT

"Stopping smoking reduces the risk of developing COPD and is an essential treatment for this inflammatory disease. Smoking cessation decreases the prevalence of respiratory symptoms, number of hospitalizations, and decline in FEV1, as well as exacerbation frequency and overall mortality."

The reference clearly states that smoking cessation is essential in reducing various harmful outcomes related to COPD.

PMID:19811377 SUPPORT

"Smoking cessation and lung volume reduction surgery would both qualify as disease-modifying interventions."

The reference identifies smoking cessation as a disease-modifying intervention, which indicates its importance in slowing disease progression and thus improving outcomes.

PMID:11935838 SUPPORT

"The most important intervention is smoking cessation."

The reference emphasizes that smoking cessation is the most important intervention to minimize the impact of COPD.

+ 1 more reference

Bronchodilators

Action: bronchodilator therapy Ontology label: Pharmacotherapy NCIT:C15986

Agent: bronchodilator NCIT:C319

Medications that relax muscles of the airways to improve airflow (e.g., beta-agonists, anticholinergics).

Show evidence (4 references)

PMID:29794201 SUPPORT

"Bronchodilator therapy can often decrease symptoms of air-flow obstruction by relaxing airway smooth muscle (bronchodilation), decreasing dyspnea, and improving quality of life."

The reference discusses how bronchodilator therapy relaxes airway smooth muscle, which improves airflow in obstructive lung diseases like COPD.

PMID:27576232 SUPPORT

"Long-acting beta2-agonists and long-acting muscarinic antagonists are first-line treatments for patients with persistently symptomatic COPD with an FEV1 of 80% or less of predicted."

This reference identifies bronchodilators, specifically long-acting beta2-agonists and muscarinic antagonists, as key treatments for COPD by improving airflow.

PMID:28757318 SUPPORT

"Combination long-acting inhaled bronchodilators are central to the management of patients with moderate to very severe chronic obstructive pulmonary disease."

This reference confirms that bronchodilators, such as long-acting beta2 agonists and long-acting muscarinic antagonists, are used to manage COPD symptoms by improving pulmonary function.

+ 1 more reference

Inhaled Corticosteroids

Action: respiratory tract agent therapy Ontology label: Pharmacotherapy NCIT:C15986

Reduce airway inflammation and frequency of exacerbations.

Show evidence (4 references)

PMID:20102305 SUPPORT

"Short-term treatment with ICS improves lung function and quality of life; in addition, several studies with longer follow-up have shown less decline over time in quality of life, and fewer exacerbations. By contrast, long-term studies have been unable to show substantial improvement in the..."

While ICS do help reduce the frequency of exacerbations and improve quality of life, the evidence on their effectiveness in reducing airway inflammation specifically is more nuanced.

PMID:37348121 SUPPORT

"Current pharmacologic strategies, including first- and second-line therapies such as long-acting β2-agonists, long-acting muscarinic antagonists, inhaled corticosteroids, phosphodiesterase-4 inhibitors, and macrolides, provide relief to patients with COPD"

ICS are included in the treatment strategies, and while they help mitigate exacerbations, the snippet suggests that not all patients experience reduced airway inflammation.

PMID:29938633 SUPPORT

"The major alteration has been in the section concerning treatment with inhalation medication - now aiming at an easy stepwise up-titration of long-acting medicine as well as a guide of how to down-titrate inhaled corticosteroids."

The guideline update underscores the role of ICS in managing stable COPD, highlighting their long-term use for reducing symptoms and managing exacerbations.

+ 1 more reference

Phosphodiesterase-4 Inhibitors

Action: Pharmacotherapy NCIT:C15986

Reduce inflammation and relax airways.

Show evidence (4 references)

PMID:15699784 SUPPORT

"Some of the selective PDE4 inhibitors have demonstrated in vitro and in vivo anti-inflammatory activity on cells commonly linked to airway inflammation in COPD, such as neutrophils."

The reference indicates that selective phosphodiesterase 4 inhibitors show anti-inflammatory activity, supporting the statement about reducing inflammation.

PMID:20649375 SUPPORT

"Roflumilast targets inflammatory processes in COPD, with beneficial effects on tobacco-induced lung inflammation, lung fibrosis and remodeling, mucociliary malfunction and oxidative stress."

Roflumilast, a PDE4 inhibitor, targets inflammatory processes, thus supporting the statement.

PMID:34731461 SUPPORT

"The orally administered PDE4 inhibitor roflumilast reduces exacerbation rates in the subgroup of chronic obstructive pulmonary disease patients with a history of exacerbations and the presence of chronic bronchitis, but can cause PDE4 related adverse effects due to systemic exposure."

This reference confirms the anti-inflammatory effect of PDE4 inhibitors which aligns with the statement.

+ 1 more reference

Oxygen Therapy

Action: Oxygen Therapy NCIT:C94624

Long-term oxygen use for patients with severe chronic hypoxemia.

Show evidence (3 references)

PMID:24461631 SUPPORT

"This therapeutic intervention has been shown to increase survival in patients with chronic obstructive pulmonary disease (COPD) and respiratory failure."

The literature supports that long-term oxygen therapy (LTOT) is used to treat patients with COPD who have severe chronic hypoxemia.

PMID:37353334 SUPPORT

"Long-term oxygen therapy (LTOT) is a mainstay treatment for patients with severe resting hypoxemia secondary to chronic respiratory conditions including COPD."

This reference specifically mentions LTOT as a primary treatment for patients with severe chronic hypoxemia due to COPD.

PMID:19462352 SUPPORT

"Only smoking cessation and long term oxygen therapy (LTOT) improve survival in COPD."

This study confirms that LTOT is a treatment that improves survival in patients with severe COPD and chronic hypoxemia.

Pulmonary Rehabilitation

Action: physical therapy Ontology label: Physical Therapy NCIT:C15302

Exercise training, education, and support to improve quality of life and physical conditioning.

Show evidence (5 references)

PMID:29526182 SUPPORT

"PR is an effective and cost-effective therapeutic intervention that improves physical performance ability, shortness of breath, and the quality of life in patients with COPD."

The reference indicates that pulmonary rehabilitation (PR) improves physical performance, shortness of breath, and quality of life in COPD patients, aligning with the statement's description of treatments including exercise training, education, and support.

PMID:34338012 SUPPORT

"Exercise improves the physiological and psychological condition of people with chronic obstructive pulmonary disease and should be encouraged, with referral to a pulmonary rehabilitation service if available."

This reference supports the statement's claim by emphasizing the importance of exercise and recommending pulmonary rehabilitation to improve the quality of life and physical conditioning in COPD patients.

PMID:34955635 SUPPORT

"The combination of drug therapy with non-drug therapy such as pulmonary rehabilitation training has demonstrated a great potential in reducing the occurrence of complications and delaying the progression of COPD."

This reference supports the statement by highlighting the benefits of pulmonary rehabilitation training, specifically its potential to improve quality of life and physical conditioning in COPD patients.

+ 2 more references

Lung Volume Reduction Surgery

Action: surgical procedure Ontology label: Surgical Procedure NCIT:C15329

Surgical removal of damaged lung tissue for severe emphysema.

Show evidence (3 references)

PMID:22189668 SUPPORT

"Surgical approaches include lung transplantation and lung volume reduction and the latter has been shown to improve exercise tolerance, quality of life, and survival in highly selected patients with advanced emphysema."

The literature supports the use of lung volume reduction surgery as a treatment for severe emphysema in chronic obstructive pulmonary disease (COPD) patients.

PMID:33926668 SUPPORT

"As symptoms and lung function decline, treatment modalities, such as lung volume reduction surgery, have been used in individuals with chronic obstructive pulmonary disease and upper lobe predominant emphysema."

The literature indicates that lung volume reduction surgery is a treatment used for severe emphysema, a condition associated with COPD.

PMID:31145187 SUPPORT

"Mortality benefits to therapy have been demonstrated in only 2 therapeutic interventions to date: long-term use of daily supplemental oxygen and surgical lung volume reduction (LVRS) for upper-lobe-predominant disease in patients with a low baseline exercise capacity."

The statement is supported as the literature suggests that lung volume reduction surgery is an established treatment for upper-lobe-predominant, severe emphysema in COPD patients.

Lung Transplantation

Action: organ transplantation Ontology label: Organ Transplantation NCIT:C15289

Considered in end-stage COPD with severe impairment.

Show evidence (4 references)

PMID:17240617 SUPPORT

"Lung transplantation is a surgical option for patients who fail optimization of medical treatment for the severe symptoms that result from COPD."

This reference states that lung transplantation is a considered treatment option for patients with severe symptoms resulting from COPD.

PMID:31375190 SUPPORT

"End-stage congestive heart failure, chronic obstructive pulmonary disease...palliative principles can guide decision making and symptom management in these disease states."

The reference focuses on end-stage COPD and mentions lung transplantation as a consideration in managing the conditions of patients.

PMID:36050206 SUPPORT

"The International Thoracic Organ Transplant Registry...focus on lung transplant recipients with chronic obstructive pulmonary disease."

This source concentrates on lung transplantation for patients with COPD, in line with the statement's context of it being a treatment for end-stage COPD.

+ 1 more reference

Mucolytic Therapy

Action: Pharmacotherapy NCIT:C15986

N-acetylcysteine and other mucolytics reduce mucus viscosity and may improve mucociliary clearance.

Macrolide Antibiotics

Action: antibiotic therapy Ontology label: Antibiotic Therapy NCIT:C15620

Long-term macrolide therapy reduces exacerbation frequency but raises antimicrobial resistance concerns.

Biologic Therapies

Action: biologic therapy Ontology label: Immunotherapy NCIT:C15262

Precision biologics targeting Type 2 inflammation in eosinophilic COPD subsets.

🌍

Environmental Factors

3

Smoking

Primary risk factor for development and progression.

Show evidence (5 references)

PMID:30810540 SUPPORT

"Although cigarette smoking is the major risk factor, only 10-20% of smokers develop COPD."

This clearly identifies smoking as a major risk factor for COPD development.

PMID:31759959 SUPPORT

"The observation that COPD is an independent risk factor for cardiovascular disease (CVDs) comes from comparisons between smokers with COPD and smokers without COPD."

This snippet highlights the relationship between smoking, COPD, and other health issues, indirectly supporting smoking as a risk factor for COPD.

PMID:28933915 SUPPORT

"The epithelial lining of the airway forms the first barrier against environmental insults, such as inhaled cigarette smoke, which is the primary risk factor for the development of chronic obstructive pulmonary disease (COPD)."

Directly states that cigarette smoke is the primary risk factor for COPD development.

+ 2 more references

Mechanism Target:

TRIGGERS Chronic Inflammation — Inhaled smoke is the irritant this node names by name, and it meets the airway epithelium with nothing in between, which is what makes the link direct. Both items are graded partial because each reports risk of the disease rather than a measurement of airway inflammation, and the second is carried precisely because it limits the claim: most smokers never develop the disease, so the exposure is not sufficient.

Show evidence (2 references)

PMID:28933915 SUPPORT Other

"The epithelial lining of the airway forms the first barrier against environmental insults, such as inhaled cigarette smoke, which is the primary risk factor for the development of chronic obstructive pulmonary disease (COPD)."

Names inhaled cigarette smoke as the environmental insult the airway epithelium meets first, and as the primary risk factor for developing the disease. The epithelial barrier is where this node begins.

PMID:30810540 SUPPORT Other

"Although cigarette smoking is the major risk factor, only 10-20% of smokers develop COPD."

Records that only 10 to 20 percent of smokers develop the disease. Carried deliberately, because it bounds what this link can be read to claim.

TRIGGERS Cuproptosis-Driven Cell Death — The review names inhaled smoke as what disrupts pulmonary copper homeostasis and so makes the microenvironment permissive for cuproptosis, which is the initiating step of the proposed metabolic-immune axis. Wired as an explicit link because the node otherwise has no upstream and its trigger would exist only as prose. The cited claim is that smoke disrupts copper handling, not that it has been shown to cause cuproptotic death in human airway tissue.

Show evidence (1 reference)

PMID:42604614 SUPPORT Other

"cigarette smoke actively disrupts pulmonary copper homeostasis"

Names the exposure as the cause of the copper dysregulation this node begins from.

Air Pollution

Exposure to pollutants can exacerbate symptoms.

Show evidence (5 references)

PMID:33542053 SUPPORT

"Our findings suggest that, when considering total personal exposure to air pollutants, mainly the gaseous pollutants affect COPD patients' health."

This study found that exposure to various air pollutants adversely affects the health of COPD patients, supporting the idea that air pollution exacerbates COPD symptoms.

PMID:25673984 SUPPORT

"The major pathogenic factors causing disease include infection and inflammation, protease and antiprotease imbalance, and oxidative stress overwhelming antioxidant defenses."

This reference discusses environmental factors, including pollutants, that contribute to oxidative stress and inflammation in COPD, thus supporting the statement.

PMID:37068517 SUPPORT

"Harmful inhaled workplace exposures can contribute to the development of chronic obstructive pulmonary disease (COPD)."

This statement supports the environmental influence on COPD, including air pollutants, as a risk factor.

+ 2 more references

Mechanism Target:

EXACERBATES Oxidative Stress and Mitochondrial Dysfunction — Inhaled pollutants are named at this node alongside cigarette smoke as drivers of mitochondrial reactive oxygen species. Recorded as exacerbating rather than triggering because both cited studies measure effects on respiratory health rather than initiation, and the intermediates are left unknown because neither measures an oxidative or mitochondrial marker. Worth stating plainly, because the smoking link into the inflammation node was graded from node wording rather than from evidence: this node's own text uses the word trigger for pollutants, and would on its face have supported a triggering grade here too. It is not taken, because that verb describes what pollutants do to reactive oxygen species production once inhaled, not whether the exposure starts the disease, and on that question the entry's own note and both cited studies say the same thing, that pollution worsens established disease. The entry does hold a paper on oxidant and antioxidant balance, but its quotable sentence names oxidative stress without naming pollution, so it cannot carry an exposure-to-node claim and is not cited here.

Show evidence (2 references)

PMID:16916323 SUPPORT Other

"Evidence from epidemiological studies finding consistent associations between air pollution and various outcomes (respiratory symptoms, reduced lung function, chronic bronchitis and mortality), has suggested that outdoor air pollution is a contributing cause of morbidity and mortality."

Epidemiological synthesis finding consistent associations between air pollution and respiratory symptoms, reduced lung function, chronic bronchitis, and mortality. It reaches health outcomes, not the oxidative step this node holds.

PMID:33542053 SUPPORT Human Clinical

"Our findings suggest that, when considering total personal exposure to air pollutants, mainly the gaseous pollutants affect COPD patients' health."

Personal-exposure measurements in patients who already have the disease, which is the design that fits an exacerbating grade. It reports effects on patient health rather than on this node.

Occupational Dust and Chemicals

Long-term exposure increases risk.

Show evidence (5 references)

PMID:11964759 SUPPORT

"occupational exposure to dusts, chemicals and gases will be considered an established, or supported by good evidence, risk factor for chronic obstructive pulmonary disease"

The abstract confirms that occupational exposure to dusts, chemicals, and gases is a well-supported risk factor for chronic obstructive pulmonary disease.

PMID:20535848 SUPPORT

"Lung function loss associated with occupational dust exposure in metal smelting"

This study provides evidence of lung function loss due to occupational dust exposure, supporting the assertion that long-term exposure to such environmental factors increases the risk of chronic obstructive pulmonary disease.

PMID:23361196 SUPPORT

"Recent studies have recognized the contribution of workplace exposures to chronic lung diseases, in particular chronic obstructive pulmonary disease (COPD)"

The abstract discusses the recognized contribution of workplace exposures, including textile dust, to chronic obstructive pulmonary disease.

+ 2 more references

Mechanism Target:

PREDISPOSES Chronic Inflammation — Workplace dusts, gases, and chemicals are an established route to the disease, but unlike cigarette smoke they are not named at this node and no cited sentence follows them as far as airway inflammation. Graded below the smoking link into this same node for that reason.

Show evidence (1 reference)

PMID:11964759 SUPPORT Other

"occupational exposure to dusts, chemicals and gases will be considered an established, or supported by good evidence, risk factor for chronic obstructive pulmonary disease"

States that occupational exposure to dusts, chemicals, and gases is an established risk factor supported by good evidence. The sentence reaches the disease, not this node.

🔬

Biochemical Markers

3

Arterial Blood Gases (Altered)

Show evidence (4 references)

PMID:21812941 SUPPORT

"The aim of this study was to identify predictors of hypoxemia, hypercapnia and increased alveolar-arterial oxygen difference in COPD patients."

The study confirms that COPD patients may show hypoxemia and hypercapnia, but it focuses on the predictors rather than just the presence of these conditions.

PMID:34756790 SUPPORT

"Respiratory acidosis with hypoxia, hypercapnia, a compensatory metabolic response, and mild hyperfibrinolysis were probably related to the combined effect of nitrogen compounds and the inhaled toxic products of detonation."

The study discusses the occurrence of hypoxia and hypercapnia in specific exposure situations, including COPD contexts.

PMID:25119324 SUPPORT

"The prevalence of this sampling method has grown among health professionals, coupled with a growing demand for domiciliary oxygen therapy in the UK, in particular for those who have chronic obstructive pulmonary disease (COPD)."

While this does not directly confirm hypoxemia and hypercapnia, it suggests the necessity of oxygen therapy for COPD patients, implying altered arterial blood gases.

+ 1 more reference

C-Reactive Protein (CRP) (Elevated)

Context: General inflammation and exacerbations.

Show evidence (5 references)

PMID:23206444 SUPPORT

"Patients with COPD had higher serum CRP concentrations than healthy controls (WMD 4.72 mg/l, 95% CI 2.98, 6.47)."

This meta-analysis suggests that patients with stable COPD had higher serum CRP concentrations than healthy controls, indicating elevated CRP in general inflammation related to COPD.

PMID:24313775 SUPPORT

"These biomarkers include C-reactive protein, procalcitonin, and peripheral blood eosinophil count, which are readily available."

The study identifies CRP as an important biomarker in COPD exacerbations, indicating its elevation in such contexts.

PMID:24102428 SUPPORT

"Serum CRP levels were also significantly higher on D1 compared to D7 (p < 0.001)."

The findings that CRP levels are elevated at the onset of COPD exacerbations support the statement.

+ 2 more references

Forced Expiratory Volume in 1 Second (FEV1) (Reduced, with a low post-bronchodilator FEV1/FVC ratio confirming persistent airflow limitation; partially reversible or more slowly declining with bronchodilator and anti-inflammatory therapy.)

Context: Spirometric pulmonary function measure (percent of predicted FEV1, together with the FEV1/FVC ratio) used to diagnose COPD, grade severity of airflow limitation, monitor disease progression, and assess pharmacodynamic response to bronchodilator and anti-inflammatory therapy. FEV1 is recognized by the FDA as a validated surrogate endpoint supporting traditional approval of COPD drugs.

Pathograph Readouts

Pharmacodynamic Marker Of Airflow Limitation Negative Pharmacodynamic

Higher or less-declining percent-predicted FEV1 indicates reduced airflow limitation; treatment-induced improvement in FEV1 reports the pharmacodynamic response to bronchodilator and anti-inflammatory therapy and underpins the FDA surrogate-endpoint basis for traditional approval of COPD drugs.

FDA-SE-adult-noncancer-013 FDA

Forced expiratory volume in 1 second (FEV1)

Traditional Validated Surrogate Endpoint

Patients with COPD

Show evidence (2 references)

PMID:19716960 SUPPORT Human Clinical

"Primary endpoints were change in prebronchodilator forced expiratory volume in 1 s (FEV(1)) and the rate of exacerbations that were moderate (glucocorticosteroid-treated) or severe."

The pivotal placebo-controlled trials of the phosphodiesterase-4 inhibitor roflumilast used change in prebronchodilator FEV1 as a primary endpoint, establishing FEV1 as a regulatory efficacy readout for COPD drug approval.

PMID:19716960 SUPPORT Human Clinical

"In a pooled analysis, prebronchodilator FEV(1) increased by 48 mL with roflumilast compared with placebo (p<0.0001)."

FEV1 improved measurably with anti-inflammatory therapy versus placebo, confirming FEV1 as a treatment-responsive pharmacodynamic marker of airflow limitation in COPD.

Show evidence (1 reference)

PMID:18836213 SUPPORT Human Clinical

"The patients were at least 40 years of age, with a forced expiratory volume in 1 second (FEV(1)) of 70% or less after bronchodilation and a ratio of FEV(1) to forced vital capacity (FVC) of 70% or less."

Reduced FEV1 and a low FEV1/FVC ratio are the spirometric criteria used to define and grade airflow limitation in COPD, supporting FEV1 as the core monitoring and severity biomarker.

📈

Progression

1

Onset

Typically begins in individuals over the age of 40.

Show evidence (2 references)

PMID:26154786 SUPPORT

"Among 657 persons who had an FEV1 of less than 80% of the predicted value before 40 years of age, 174 (26%) had COPD after 22 years of observation, whereas among 2207 persons who had a baseline FEV1 of at least 80% of the predicted value before 40 years of age, 158 (7%) had COPD after 22 years..."

The literature suggests that COPD can develop in individuals with low FEV1 before the age of 40. While this supports the idea that COPD typically begins in individuals over 40, it also indicates that it can start earlier in some cases.

PMID:19934351 SUPPORT

"There is growing evidence of higher prevalence of chronic obstructive pulmonary disease (COPD) in the elderly. Age-associated changes in the structure and function of the lung may increase a pathogenetic susceptibility to COPD."

This reference supports the statement that COPD typically begins in individuals over the age of 40, particularly due to age-associated changes in lung structure and function.

📊

Prevalence

1

Global

Point Prevalence 11700.0 per 100,000 >1 in 1,000

Show evidence (2 references)

PMID:35261410 NO_EVIDENCE

"The estimated pooled prevalence of COPD was 11.1% (95% confidence interval, CI: 7.4-14.8%), using the Global Initiative for Chronic Obstructive Lung Disease fixed criteria and 8.0% (95% CI: 5.6-10.4%) using the lower limit of normal criteria."

The study provides prevalence data for specific regions (e.g., South Asia) but does not mention a global prevalence rate of 11.7%.

PMID:37461046 NO_EVIDENCE

"Though disease burden of silicosis has been on a decline in general from 1990 to 2019, which shows a promising prospect but cannot be ignored."

This study focuses on the global incidence, prevalence, and disease burden of silicosis, not COPD.

📊

Related Datasets

3

Integrative multi-omic analyses identify major axes of heterogeneity in chronic obstructive pulmonary disease and uncover their molecular contributors - ECLIPSE replication cohort geo:GSE324136

Chronic Obstructive Pulmonary Disease (COPD) is a complex, heterogeneous disease. Traditional subtyping methods generally focus on either the clinical manifestations or the molecular endotypes of the disease, leading to classifications that only partially reflect disease heterogeneity. Here, we introduce a variational autoencoder-based subtyping pipeline that jointly embeds clinical and gene expression data into a single subject-level representation. We evaluate the framework in the COPDGene study, a large study of current and former smoking individuals with and without COPD.

human MICROARRAY n=628

Identified by GEO DataSets index search for Chronic Obstructive Pulmonary Disease (scripts/discover_datasets.py); accession and metadata verified against NCBI E-utilities on 2026-07-31. Title, sample count, and organism are GEO's own values.

Multi-omics analyses of airway host-microbe interactions in chronic obstructive pulmonary disease identify potential therapeutic interventions ega:EGAS00001006398

The mechanistic role of the airway microbiome in chronic obstructive pulmonary disease (COPD) remains largely unexplored. We present a landscape of airway microbe-host interactions in COPD through an in-depth profiling of the sputum metagenome, metabolome, host transcriptome and proteome from 99 COPD patients and 36 healthy individuals in China.

human

European Genome-phenome Archive study, matched because the disease is named in the study's own title ("Chronic Obstructive Pulmonary Disease"); description-level mentions were not accepted. EGA study_type: Other. Controlled access -- data require a Data Access Agreement. EGA metadata retrieved 2026-08-01.

Airway Dysbiosis Accelerates Lung Function Decline in Chronic Obstructive Pulmonary Disease ega:EGAS00001006444

This repository contains human sample derived microbiome full-length 16S rRNA sequencing data for sputum samples in COPD patients. The project goal is to understand the association of the lung microbiome with accelerated lung function decline in COPD patients.

human

European Genome-phenome Archive study, matched because the disease is named in the study's own title ("Chronic Obstructive Pulmonary Disease"); description-level mentions were not accepted. EGA study_type: Other. Controlled access -- data require a Data Access Agreement. EGA metadata retrieved 2026-08-01.

🧫

Experimental Models

2

Open-top vascularized alveolus-on-chip whole cigarette smoke model ORGAN_ON_CHIP namo:OrganOnChip

A membrane-free, open-top alveolus-on-chip in which primary human lung endothelial cells and pericytes self-assemble into a perfusable three-dimensional microvascular network, with alveolar type 2 epithelial cells cultured directly on the vascularized hydrogel. The open top permits exposure to whole cigarette smoke rather than to smoke extract, so the exposure is airborne and confined to the epithelial surface.

Organism

human NCBITaxon:9606

Tissue

alveolus of lung UBERON:0002299

Cell source

Primary human lung endothelial cells, pericytes, and alveolar type 2 cells, including cells from stage II and stage IV COPD patients

Culture

Open-top membrane-free microfluidic chip with self-assembled perfusable vascular network

Publication

PMID:42473541

Pathograph links

Alveolar Destruction partially recapitulates fidelity: moderate Repeated whole cigarette smoke exposure disintegrated the alveolar microvascular network. The informative control is that the epithelium itself stayed intact and that vascular networks exposed to smoke without an overlying epithelium were undamaged, which locates the vascular injury downstream of an epithelial signal rather than in direct smoke contact. This supports the vascular limb of the alveolar destruction in emphysema.

Limitations: The AEC2-dependence experiment rests on two donors and is described by the authors as preliminary; the mediating epithelial factors are unidentified. The model also captures capillary loss over days rather than the airspace enlargement and elastin degradation that define emphysema over decades, and it has no infiltrating leukocytes.

Readouts

Integrity of the alveolar endothelial-pericyte vascular network

Direction: DECREASED

Interpretation: Loss of continuous CD31-positive vessels after smoke exposure is the microvascular correlate of alveolar destruction.

Show evidence (1 reference)

PMID:42473541 SUPPORT In Vitro

"Importantly, exposure of the AEC2 layer to whole cigarette smoke (WCS) led to disintegration of the underlying vascular network, an effect not observed in the absence of AEC2."

Reports both the vascular disintegration and the epithelium-dependence control.

Alveolar epithelial monolayer morphology after smoke exposure

Direction: UNCHANGED

Interpretation: The directly exposed epithelium was preserved while the unexposed endothelium failed, a negative result that reverses the expected order of susceptibility.

Show evidence (1 reference)

PMID:42473541 SUPPORT In Vitro

"Here, we demonstrated that endothelial cells were more susceptible to cigarette smoke exposure compared to AEC2 as vascular networks disintegrated while the alveolar epithelium remained intact."

Documents the preserved epithelium alongside the failed endothelium.

Show evidence (1 reference)

PMID:42473541 SUPPORT In Vitro

"These data are however still preliminary and need further repetition and expansion to identify AEC2-derived factors involved in the disintegration of the vascular networks upon smoke exposure."

The authors' own statement that the epithelium-mediated mechanism is preliminary; PARTIAL records the model as informative but not yet established for this node.

Oxidative Stress and Mitochondrial Dysfunction measures fidelity: low The platform delivers a controlled, repeated airborne whole-smoke exposure to human alveolar cells and supports perfusion of monocytes through the vascular network, providing a route to measure smoke-induced injury and immune recruitment together.

Limitations: This study reported structural and gene-expression endpoints rather than direct measurements of reactive oxygen species or mitochondrial function, so support for this node is by exposure relevance rather than by a matching readout.

Show evidence (1 reference)

PMID:42473541 SUPPORT In Vitro

"Of note, we also confirmed that pulmonary endothelial cells isolated from two different COPD patients (stage II and stage IV) were able to form vascular networks"

Establishes that patient-derived COPD endothelium can be used in the platform, supporting disease relevance; PARTIAL because no oxidative-stress readout was reported.

Patient-derived epithelial-endothelial COPD airway-on-a-chip ORGAN_ON_CHIP namo:OrganOnChip

A perfused airway-on-a-chip pairing primary airway epithelial cells with pulmonary microvascular endothelial cells under air-liquid interface, built in matched healthy-donor and COPD-patient versions so the two can be compared under identical culture conditions. Using patient-derived cells on both sides of the barrier preserves the donor's disease phenotype rather than inducing one with an exposure.

Organism

human NCBITaxon:9606

Tissue

epithelium of bronchus UBERON:0002031

Cell source

Primary airway epithelial and pulmonary microvascular endothelial cells from COPD patients and healthy donors

Culture

Perfused microfluidic airway-on-a-chip at air-liquid interface

Publication

PMID:42475431

Pathograph links

Mucus Hypersecretion recapitulates fidelity: moderate Chips built from COPD patient cells showed enhanced mucus production relative to healthy-donor chips under identical conditions, reproducing a cardinal COPD phenotype without any exposure being applied.

Limitations: The mucus phenotype appeared without the loss of barrier function or cell viability seen in advanced disease, so the model represents the secretory abnormality in isolation. Donor numbers are small and the protocol is published as a methods article rather than a powered comparative study.

Readouts

Mucus production in COPD-derived versus healthy-donor chips

Direction: INCREASED

Interpretation: Increased mucus in patient-derived epithelium under identical conditions attributes the phenotype to the cells rather than to the exposure.

Show evidence (1 reference)

PMID:42475431 SUPPORT In Vitro

"The COPD model recapitulated key features of the disease, notably enhanced mucus production, without compromising barrier function or cell viability."

Reports the mucus phenotype and its limits in the same sentence.

Show evidence (1 reference)

PMID:42475431 SUPPORT In Vitro

"The use of patient-derived epithelial and endothelial cells preserves individual pathological characteristics, enabling investigation of intercellular mechanisms in COPD."

Supports the patient-derived chip as carrying genuine COPD phenotype into the model.

Airway Remodeling measures fidelity: low The chip supports full mucociliary differentiation with ciliary beating and permits compartment-specific RNA extraction, giving a route to measure epithelial differentiation state and epithelial-endothelial crosstalk in COPD cells.

Limitations: Barrier integrity and junctional localization were preserved in the COPD chips, so the model does not reproduce the structural remodelling — subepithelial fibrosis, smooth muscle thickening, squamous metaplasia — that this node describes. It is a platform for measuring remodelling signals, not a model of the remodelled airway.

Show evidence (1 reference)

PMID:42475431 SUPPORT In Vitro

"Permeability assays demonstrated robust barrier integrity in both systems, while immunofluorescence confirmed continuous localization of Zonula Occludens-1 (ZO-1) and vascular endothelial cadherin (VE-cadherin) at cell junctions."

Preserved barrier and junctions in both healthy and COPD chips bound what this model can say about remodelling; PARTIAL reflects that limit.

{ }

Source YAML

click to show

name: Chronic_Obstructive_Pulmonary_Disease
creation_date: '2025-12-04T16:57:31Z'
description: >-
  Chronic obstructive pulmonary disease is a progressive disorder of persistent,
  incompletely reversible airflow limitation caused by chronic inflammation of
  the airways and lung parenchyma, most often from long-term inhalation of
  cigarette smoke or other noxious particles. The inflammatory response drives a
  protease-antiprotease imbalance and oxidative stress that destroy alveolar
  walls (emphysema) and produce small-airway fibrosis and mucus hypersecretion
  (chronic bronchitis), reducing elastic recoil and increasing airflow
  resistance. The result is chronic dyspnea, cough, and sputum production with
  recurrent exacerbations, air trapping, and hyperinflation, and in advanced
  disease hypoxemia and cor pulmonale.
category: Complex
parents:
- Respiratory Disease
- Smoking-Related Disease
has_subtypes:
- name: Chronic Bronchitis
  description: Inflammation of the bronchial tubes leading to increased mucus production and chronic cough.
  evidence:
  - reference: PMID:23204254
    reference_title: "Chronic bronchitis and chronic obstructive pulmonary disease."
    supports: SUPPORT
    snippet: Chronic bronchitis (CB) is a common but variable phenomenon in chronic obstructive pulmonary disease (COPD).
    explanation: The article clearly states that Chronic Bronchitis (CB) is a subtype of COPD, characterized by inflammation of the bronchial tubes leading to increased mucus production and chronic cough.
  - reference: PMID:27264777
    reference_title: "Management of chronic obstructive pulmonary disease beyond the lungs."
    supports: SUPPORT
    snippet: Chronic obstructive pulmonary disease (COPD) is an umbrella term that covers many clinical subtypes with clearly different pulmonary and extra-pulmonary characteristics.
    explanation: The article supports that COPD has multiple subtypes with differing characteristics, encompassing conditions like Chronic Bronchitis.
  - reference: PMID:22753831
    reference_title: "Chronic cough and sputum production: a clinical COPD phenotype?"
    supports: SUPPORT
    snippet: 'Chronic cough and sputum production: a clinical COPD phenotype?'
    explanation: The article discusses the phenotype of COPD which includes chronic cough and sputum production, indicative of conditions like Chronic Bronchitis.
- name: Emphysema
  description: Damage to the alveoli resulting in shortness of breath and reduced surface area for gas exchange.
  evidence:
  - reference: PMID:33926668
    reference_title: "Alpha(1)-antitrypsin Disease, Treatment and Role for Lung Volume Reduction Surgery."
    supports: SUPPORT
    snippet: 'Chronic obstructive pulmonary usually is subcategorized into 2 groups: chronic bronchitis and emphysema.'
    explanation: This reference reiterates the point that emphysema is a recognized subtype of COPD.
  - reference: PMID:21178627
    reference_title: "Emphysema and chronic obstructive pulmonary disease in coal miners."
    supports: SUPPORT
    snippet: Latest studies further support the association of emphysema and COPD with coal dust exposure.
    explanation: This confirms that emphysema is considered a subtype of COPD, further supporting the statement.
prevalence:
- population: Global
  measure_type: POINT_PREVALENCE
  prevalence_class: ABOVE_1_IN_1000
  rate_per_100000: 11700.0
  percentage: 11.7
  evidence:
  - reference: PMID:35261410
    reference_title: "Prevalence of chronic obstructive pulmonary disease and chronic bronchitis in eight countries: a systematic review and meta-analysis."
    supports: NO_EVIDENCE
    snippet: 'The estimated pooled prevalence of COPD was 11.1% (95% confidence interval, CI: 7.4-14.8%), using the Global Initiative for Chronic Obstructive Lung Disease fixed criteria and 8.0% (95% CI: 5.6-10.4%) using the lower limit of normal criteria.'
    explanation: The study provides prevalence data for specific regions (e.g., South Asia) but does not mention a global prevalence rate of 11.7%.
  - reference: PMID:37461046
    reference_title: "Global incidence, prevalence and disease burden of silicosis: 30 years' overview and forecasted trends."
    supports: NO_EVIDENCE
    snippet: Though disease burden of silicosis has been on a decline in general from 1990 to 2019, which shows a promising prospect but cannot be ignored.
    explanation: This study focuses on the global incidence, prevalence, and disease burden of silicosis, not COPD.
progression:
- phase: Onset
  notes: Typically begins in individuals over the age of 40.
  evidence:
  - reference: PMID:26154786
    reference_title: "Lung-Function Trajectories Leading to Chronic Obstructive Pulmonary Disease."
    supports: SUPPORT
    snippet: Among 657 persons who had an FEV1 of less than 80% of the predicted value before 40 years of age, 174 (26%) had COPD after 22 years of observation, whereas among 2207 persons who had a baseline FEV1 of at least 80% of the predicted value before 40 years of age, 158 (7%) had COPD after 22 years of observation.
    explanation: The literature suggests that COPD can develop in individuals with low FEV1 before the age of 40. While this supports the idea that COPD typically begins in individuals over 40, it also indicates that it can start earlier in some cases.
  - reference: PMID:19934351
    reference_title: "The aging lung and chronic obstructive pulmonary disease: similarity and difference."
    supports: SUPPORT
    snippet: There is growing evidence of higher prevalence of chronic obstructive pulmonary disease (COPD) in the elderly. Age-associated changes in the structure and function of the lung may increase a pathogenetic susceptibility to COPD.
    explanation: This reference supports the statement that COPD typically begins in individuals over the age of 40, particularly due to age-associated changes in lung structure and function.
pathophysiology:
- name: Airflow Limitation
  description: Obstruction of airflow due to inflammation, mucus build-up, and remodeling of the airways.
  cell_types:
  - preferred_term: Epithelial Cell
    term:
      id: CL:0000066
      label: epithelial cell
  biological_processes:
  - preferred_term: inflammatory response
    term:
      id: GO:0006954
      label: inflammatory response
  - preferred_term: airway remodeling
    description: Structural changes in airway architecture
  locations:
  - preferred_term: bronchus
    term:
      id: UBERON:0002185
      label: bronchus
  - preferred_term: small airway
    description: Terminal and respiratory bronchioles
  downstream:
  - target: Progressive Respiratory Impairment
    description: Chronic airway inflammation and remodeling lead to progressive airflow obstruction and respiratory decline.
    evidence:
    - reference: PMID:39046133
      reference_title: "Small airways disease in chronic obstructive pulmonary disease."
      supports: SUPPORT
      snippet: Chronic exposure to smoking and noxious particles or gases induces inflammation and remodeling, leading to airway obstruction and SAD, eventually resulting in complete airway loss.
      explanation: This 2024 review establishes that chronic inflammation and remodeling cause irreversible airflow limitation and progressive respiratory decline in COPD.
  evidence:
  - reference: PMID:23204254
    reference_title: "Chronic bronchitis and chronic obstructive pulmonary disease."
    supports: SUPPORT
    snippet: CB is caused by overproduction and hypersecretion of mucus by goblet cells, which leads to worsening airflow obstruction by luminal obstruction of small airways, epithelial remodeling, and alteration of airway surface tension predisposing to collapse
    explanation: This study describes how mucus build-up and epithelial remodeling lead to airflow obstruction in COPD.
  - reference: PMID:36108172
    reference_title: "Anomalous Epithelial Variations and Ectopic Inflammatory Response in Chronic Obstructive Pulmonary Disease."
    supports: SUPPORT
    snippet: Phenotypic alterations in the lung epithelium have been widely implicated in chronic obstructive pulmonary disease (COPD) pathogenesis, but the precise mechanisms orchestrating this persistent inflammatory process remain unknown.
    explanation: This study notes the involvement of epithelial cells in COPD but states that mechanisms remain unknown, partially supporting the role of epithelial cells in airflow obstruction.
  - reference: PMID:38625125
    reference_title: "Revisiting airway epithelial dysfunction and mechanisms in chronic obstructive pulmonary disease: the role of mitochondrial damage."
    supports: SUPPORT
    snippet: Chronic exposure to environmental hazards causes airway epithelial dysfunction, primarily impaired physical barriers, immune dysfunction, and repair or regeneration. Impairment of airway epithelial function subsequently leads to exaggerated airway inflammation and remodeling, the main features of chronic obstructive pulmonary disease (COPD).
    explanation: This study supports the statement by highlighting the role of epithelial dysfunction, inflammation, and remodeling in COPD pathophysiology.
- name: Chronic Inflammation
  description: Persistent irritation from inhaled substances like cigarette smoke leads to airway and alveolar inflammation.
  cell_types:
  - preferred_term: Neutrophil
    term:
      id: CL:0000775
      label: neutrophil
  - preferred_term: Macrophage
    term:
      id: CL:0000235
      label: macrophage
  - preferred_term: T-lymphocyte
    term:
      id: CL:0000084
      label: T cell
  biological_processes:
  - preferred_term: inflammatory response
    term:
      id: GO:0006954
      label: inflammatory response
  - preferred_term: neutrophil degranulation
    term:
      id: GO:0043312
      label: neutrophil degranulation
  locations:
  - preferred_term: bronchus
    term:
      id: UBERON:0002185
      label: bronchus
  - preferred_term: alveolus of lung
    term:
      id: UBERON:0002299
      label: alveolus of lung
  downstream:
  - target: Cuproptosis-Driven Cell Death
    hypothesis_groups:
    - emerging_cuproptosis_metabolic_immune_axis
    causal_link_type: DIRECT
    description: >-
      Return arm of the proposed metabolic-immune axis: the inflammatory milieu
      impairs copper handling in cells that survived the first round of
      cuproptosis, sensitizing them to a further round. Modelled as an edge
      rather than left in prose so the cycle the review describes is visible in
      the pathograph, and grouped under the emerging hypothesis because the loop
      is proposed rather than demonstrated.
    evidence:
    - reference: PMID:42604614
      reference_title: "Cuproptosis: The metabolic-immune axis in chronic obstructive pulmonary disease pathogenesis and therapeutics."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: this inflammatory milieu further impairs copper handling in surviving cells, sensitizing them to subsequent death
      explanation: States the inflammation-to-cuproptosis arm that this edge represents.
  evidence:
  - reference: PMID:17305517
    reference_title: "Inflammatory cells and chronic obstructive pulmonary disease."
    supports: SUPPORT
    snippet: Neutrophils and macrophages have been implicated in this process; they release proteolytic enzymes and generate oxidants, which cause tissue damage, as well as cytokines and chemokines, which can potentiate inflammation and trigger an immune response.
    explanation: The literature describes the involvement of neutrophils, macrophages, and T-lymphocytes in the inflammatory process associated with COPD, supporting the notion of persistent irritation and chronic inflammation.
  - reference: PMID:24507838
    reference_title: "Cellular and molecular mechanisms of chronic obstructive pulmonary disease."
    supports: SUPPORT
    snippet: This inflammation is characterized by increased numbers of alveolar macrophages, neutrophils, and T lymphocytes, which are recruited from the circulation.
    explanation: This article further substantiates the involvement of these cell types (neutrophils, macrophages, and T-lymphocytes) in the pathophysiology of COPD, linking them to chronic inflammation.
  - reference: PMID:38035712
    reference_title: "Characteristics of inflammatory phenotypes in patients with chronic obstructive pulmonary disease: a cross-sectional study."
    supports: SUPPORT
    snippet: In this study, we found that neutrophilic phenotype (NP, 58.0%) was the most common airway inflammation phenotype in patients with COPD, followed by mixed granulocytic phenotype (MGP, 32.6%).
    explanation: The study indicates that neutrophils are predominant in COPD, supporting the statement about chronic inflammation.
  - reference: PMID:38891820
    reference_title: "Macrophage Polarization and Functions in Pathogenesis of Chronic Obstructive Pulmonary Disease."
    supports: SUPPORT
    snippet: Recent multiomics-based evidence suggests that the plasticity of alveolar macrophages contributes to the onset and progression of COPD through the coordinated modulation of numerous transcription factors.
    explanation: The article highlights the role of macrophages in the pathogenesis and progression of COPD, thus supporting the statement.
  - reference: PMID:11993785
    reference_title: "Pathology and pathophysiology of chronic obstructive pulmonary disease."
    supports: SUPPORT
    snippet: The characteristic changes in the central airways include inflammatory cellular infiltration into the airway wall and mucous gland enlargement.
    explanation: This reference provides a broader overview of the pathological changes in COPD, mentioning inflammatory cells but not specifically detailing the involvement of neutrophils, macrophages, and T-lymphocytes.
- name: Airway Remodeling
  description: Structural changes in the airway due to chronic inflammation, including fibrosis and increased airway thickness.
  cell_types:
  - preferred_term: Smooth Muscle Cell
    term:
      id: CL:0000192
      label: smooth muscle cell
  biological_processes:
  - preferred_term: extracellular matrix organization
    term:
      id: GO:0030198
      label: extracellular matrix organization
  - preferred_term: fibrosis
    description: Excessive deposition of connective tissue
  locations:
  - preferred_term: bronchus
    term:
      id: UBERON:0002185
      label: bronchus
  - preferred_term: small airway
    description: Terminal and respiratory bronchioles
  evidence:
  - reference: PMID:20500603
    reference_title: "Pathological airway remodelling in inflammation."
    supports: SUPPORT
    snippet: Moreover, airway remodelling occurs not only in asthma but also in several pulmonary disorders such as chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis and systemic sclerosis.
    explanation: The statement aligns with the mentioned literature which notes airway remodeling as part of chronic obstructive pulmonary disease.
  - reference: PMID:30257694
    reference_title: "Roles of airway smooth muscle dysfunction in chronic obstructive pulmonary disease."
    supports: SUPPORT
    snippet: Multiple dysfunctions of ASM contribute to modulating airway responses to stimuli, remodeling, and fibrosis, as well as influence the compliance of lungs.
    explanation: The statement is supported as this literature highlights the role of airway smooth muscle cells in airway remodeling and fibrosis in COPD.
  - reference: PMID:15347849
    reference_title: "Differences in airway remodeling between asthma and chronic obstructive pulmonary disease."
    supports: SUPPORT
    snippet: Increases in airway smooth muscle mass occur in large airways of severe asthmatics and in small airways of patients with COPD.
    explanation: The literature supports the statement by confirming the involvement of smooth muscle cells and structural changes in the airways in COPD.
- name: Alveolar Destruction
  description: Breakdown of alveolar walls, leading to reduced surface area for gas exchange and loss of lung elasticity.
  cell_types:
  - preferred_term: Alveolar Macrophage
    term:
      id: CL:0000583
      label: alveolar macrophage
  biological_processes:
  - preferred_term: proteolysis
    term:
      id: GO:0006508
      label: proteolysis
  - preferred_term: extracellular matrix organization
    term:
      id: GO:0030198
      label: extracellular matrix organization
  locations:
  - preferred_term: alveolus of lung
    term:
      id: UBERON:0002299
      label: alveolus of lung
  - preferred_term: lung parenchyma
    term:
      id: UBERON:0008946
      label: lung parenchyma
  evidence:
  - reference: PMID:11993785
    reference_title: "Pathology and pathophysiology of chronic obstructive pulmonary disease."
    supports: SUPPORT
    snippet: In the lung parenchyma, emphysema defined as alveolar destruction and airspace enlargement is present.
    explanation: While the reference supports alveolar destruction as part of COPD's pathophysiology, it does not mention alveolar macrophages specifically.
  - reference: PMID:29433833
    reference_title: "Macrophage phagocytosis cracking the defect code in COPD."
    supports: SUPPORT
    snippet: In inflammatory lung diseases such as chronic obstructive pulmonary disease (COPD), despite their increased numbers, macrophages demonstrate significantly reduced phagocytic capacity of bacteria and apoptotic cells.
    explanation: The macrophages' role in the pathophysiology of COPD is discussed, focusing on their reduced phagocytic capacity rather than direct alveolar destruction.
  - reference: PMID:32493486
    reference_title: "Alveolar lipids in pulmonary disease. A review."
    supports: SUPPORT
    snippet: External insults like smoke and pollution can disturb surfactant homeostasis and result in either surfactant insufficiency or accumulation. But disruption of surfactant homeostasis is also observed in many chronic adult diseases, including chronic obstructive pulmonary disease (COPD).
    explanation: The role of alveolar macrophages (responsible for the degradation of surfactant) in the development of COPD is mentioned, but no direct link to alveolar destruction.
  - reference: PMID:24707174
    reference_title: "The role of microparticles in chronic obstructive pulmonary disease."
    supports: SUPPORT
    snippet: 'There are eight types of EMPs which are defined by the presence of different endothelial markers on the cell membrane: vascular endothelial-cadherin; platelet endothelial cell adhesion molecule; melanoma cell adhesion molecule; E-selectin; CD51; CD105; von Willebrand factor; and CD143 EMPs.'
    explanation: The reference discusses endothelial injury and microparticles in COPD, which may indirectly relate to alveolar destruction, but does not directly address it or the role of alveolar macrophages.
- name: Oxidative Stress and Mitochondrial Dysfunction
  description: Cigarette smoke and pollutants trigger mitochondrial ROS production, impaired mitophagy, and reduced antioxidant defenses, amplifying inflammation.
  cell_types:
  - preferred_term: airway epithelial cell
    term:
      id: CL:0002368
      label: respiratory tract epithelial cell
  - preferred_term: Alveolar Macrophage
    term:
      id: CL:0000583
      label: alveolar macrophage
  biological_processes:
  - preferred_term: response to oxidative stress
    term:
      id: GO:0006979
      label: response to oxidative stress
  - preferred_term: mitochondrion organization
    term:
      id: GO:0007005
      label: mitochondrion organization
  - preferred_term: mitophagy
    term:
      id: GO:0000422
      label: autophagy of mitochondrion
  locations:
  - preferred_term: bronchus
    term:
      id: UBERON:0002185
      label: bronchus
  - preferred_term: alveolus of lung
    term:
      id: UBERON:0002299
      label: alveolus of lung
  notes: Reduced Nrf2 and SIRT1 activity diminishes antioxidant capacity; mitochondrial ROS activates NLRP3 inflammasome.
  downstream:
  - target: Protease-Antiprotease Imbalance (MMP-2/TIMP-2 Axis)
    description: Oxidative stress activates NF-κB, MAPK, and AP-1 signaling, which upregulates MMP-2 and dysregulates TIMP-2 — the disorder-specific form of the module's Oxidant and Inflammatory Trigger edge into Protease-Antiprotease Imbalance.
  evidence:
  - reference: PMID:42181267
    reference_title: "Emerging role of SIRT1 in asthma and COPD from molecular mechanisms to translational therapy."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Shared benefits include mitigation of oxidative stress, mitochondrial dysfunction, and extracellular matrix remodeling
    explanation: This review identifies mitigation of oxidative stress as a shared benefit of SIRT1 activation in obstructive airway disease, supporting SIRT1's role as a regulator of oxidative stress in COPD.
- name: Mucus Hypersecretion
  description: Upregulation of MUC5AC and MUC5B, goblet cell hyperplasia, and impaired mucociliary clearance contribute to mucus plugging.
  cell_types:
  - preferred_term: goblet cell
    term:
      id: CL:0000160
      label: goblet cell
  - preferred_term: club cell
    term:
      id: CL:0000158
      label: club cell
  biological_processes:
  - preferred_term: mucus secretion
    term:
      id: GO:0070254
      label: mucus secretion
  - preferred_term: cilium movement
    term:
      id: GO:0003341
      label: cilium movement
  locations:
  - preferred_term: bronchus
    term:
      id: UBERON:0002185
      label: bronchus
  - preferred_term: small airway
    description: Terminal and respiratory bronchioles
  notes: MUC5AC/MUC5B overexpression and club-to-goblet transdifferentiation impair airway clearance.
- name: NLRP3 Inflammasome Activation
  description: Mitochondrial ROS and particulate exposures activate NLRP3 inflammasome, leading to caspase-1 activation and IL-1β/IL-18 release.
  cell_types:
  - preferred_term: Macrophage
    term:
      id: CL:0000235
      label: macrophage
  - preferred_term: airway epithelial cell
    term:
      id: CL:0002368
      label: respiratory tract epithelial cell
  biological_processes:
  - preferred_term: inflammatory response
    term:
      id: GO:0006954
      label: inflammatory response
  cellular_components:
  - preferred_term: NLRP3 inflammasome complex
    term:
      id: GO:0072559
      label: NLRP3 inflammasome complex
  locations:
  - preferred_term: bronchus
    term:
      id: UBERON:0002185
      label: bronchus
  - preferred_term: alveolus of lung
    term:
      id: UBERON:0002299
      label: alveolus of lung
  notes: PM2.5 and cigarette smoke synergize to activate NLRP3/caspase-1 signaling.
- name: Cellular Senescence
  description: Senescent epithelial, fibroblast, and immune cells exhibit senescence-associated secretory phenotype (SASP), promoting chronic inflammation and remodeling.
  cell_types:
  - preferred_term: airway epithelial cell
    term:
      id: CL:0002368
      label: respiratory tract epithelial cell
  - preferred_term: fibroblast
    term:
      id: CL:0000057
      label: fibroblast
  biological_processes:
  - preferred_term: cellular senescence
    term:
      id: GO:0090398
      label: cellular senescence
  - preferred_term: inflammatory response
    term:
      id: GO:0006954
      label: inflammatory response
  locations:
  - preferred_term: lung
    term:
      id: UBERON:0002048
      label: lung
  notes: SASP factors include IL-6, CXCL8, and MMPs; senolytic therapies are under investigation.
- name: SIRT1-Mediated NAD+ Signaling and Protective Deacetylation
  description: SIRT1 (Sirtuin 1), an NAD+-dependent deacetylase, exerts protective effects in COPD by inhibiting pro-inflammatory signaling pathways (NF-κB, STAT3) while activating stress-response transcription factors (Nrf2, FOXO3) and suppressing pro-fibrotic TGF-β/Smad signaling. In COPD, SIRT1 reduces neutrophilic inflammation, mitigates alveolar senescence, and helps restore protease/antiprotease balance. SIRT1 also mitigates oxidative stress and mitochondrial dysfunction.
  downstream:
  - target: Chronic Inflammation
    description: SIRT1-mediated deacetylation inhibits NF-κB and STAT3 signaling, reducing neutrophilic recruitment and pro-inflammatory cytokine production.
  - target: Cellular Senescence
    description: SIRT1 suppresses senescence-associated secretory phenotype (SASP) and promotes cell viability in epithelial and immune cells.
  - target: Alveolar Destruction
    description: SIRT1 suppresses TGF-β/Smad pro-fibrotic signaling and restores protease/antiprotease balance through Nrf2-mediated antioxidant responses.
  - target: Oxidative Stress and Mitochondrial Dysfunction
    description: SIRT1 activation of Nrf2 and FOXO3 enhances antioxidant defenses and mitochondrial homeostasis, reducing ROS-driven inflammasome activation.
  biological_processes:
  - preferred_term: protein deacetylation
    term:
      id: GO:0006476
      label: protein deacetylation
  - preferred_term: response to oxidative stress
    term:
      id: GO:0006979
      label: response to oxidative stress
  - preferred_term: transcriptional regulation
    term:
      id: GO:0006355
      label: regulation of DNA-templated transcription
  - preferred_term: negative regulation of inflammatory response
    term:
      id: GO:0050728
      label: negative regulation of inflammatory response
  cell_types:
  - preferred_term: Neutrophil
    term:
      id: CL:0000775
      label: neutrophil
  - preferred_term: Airway Epithelial Cell
    term:
      id: CL:0002368
      label: respiratory tract epithelial cell
  - preferred_term: Alveolar Macrophage
    term:
      id: CL:0000583
      label: alveolar macrophage
  genes:
  - preferred_term: SIRT1
    term:
      id: hgnc:14929
      label: SIRT1
  - preferred_term: NFKB1
    term:
      id: hgnc:7794
      label: NFKB1
  - preferred_term: STAT3
    term:
      id: hgnc:11364
      label: STAT3
  - preferred_term: NFE2L2
    term:
      id: hgnc:7782
      label: NFE2L2
  - preferred_term: FOXO3
    term:
      id: hgnc:3821
      label: FOXO3
  - preferred_term: TGFB1
    term:
      id: hgnc:11766
      label: TGFB1
  evidence:
  - reference: PMID:42181267
    reference_title: "Emerging role of SIRT1 in asthma and COPD from molecular mechanisms to translational therapy."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "SIRT1, an NAD+-dependent deacetylase, exerting protective effects by inhibiting NF-κB and STAT3, activating Nrf2 and FOXO3, and suppressing TGF-β/Smad."
    explanation: This review identifies the key molecular mechanisms through which SIRT1 exerts protective effects in COPD by targeting multiple pro-inflammatory and pro-fibrotic pathways.
  - reference: PMID:42181267
    reference_title: "Emerging role of SIRT1 in asthma and COPD from molecular mechanisms to translational therapy."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "in COPD, it reduces neutrophilic inflammation, alveolar senescence, and protease/antiprotease imbalance."
    explanation: This review explicitly describes SIRT1's protective effects specific to COPD pathophysiology, directly addressing three key pathological mechanisms.
  - reference: PMID:42181267
    reference_title: "Emerging role of SIRT1 in asthma and COPD from molecular mechanisms to translational therapy."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Shared benefits include mitigation of oxidative stress, mitochondrial dysfunction, and extracellular matrix remodeling."
    explanation: Describes SIRT1's shared protective mechanisms across multiple pathophysiological domains relevant to asthma and COPD.
- name: Protease-Antiprotease Imbalance (MMP-2/TIMP-2 Axis)
  conforms_to: emphysema_protease_antiprotease_imbalance#Protease-Antiprotease Imbalance
  biological_scale: MOLECULAR
  description: Oxidative stress dysregulates the matrix metalloproteinase-2 (MMP-2) to tissue inhibitor of metalloproteinase-2 (TIMP-2) ratio, tipping the balance toward unopposed proteolysis of the alveolar extracellular matrix. Cigarette smoke and particulate matter exposure activate inflammatory signaling (NF-κB, MAPK, AP-1) that upregulates MMP-2 expression and suppresses TIMP-2 activity, resulting in enhanced degradation of lung elastic fibers and collagen. Genetic polymorphisms in MMP-2 and TIMP-2 influence individual susceptibility and disease severity.
  cell_types:
  - preferred_term: Neutrophil
    term:
      id: CL:0000775
      label: neutrophil
  - preferred_term: Alveolar Macrophage
    term:
      id: CL:0000583
      label: alveolar macrophage
  biological_processes:
  - preferred_term: Proteolysis
    term:
      id: GO:0006508
      label: proteolysis
    modifier: INCREASED
  - preferred_term: Extracellular Matrix Disassembly
    term:
      id: GO:0022617
      label: extracellular matrix disassembly
    modifier: INCREASED
  - preferred_term: Response to Oxidative Stress
    term:
      id: GO:0006979
      label: response to oxidative stress
  downstream:
  - target: Alveolar Destruction
    description: Unopposed MMP-2 proteolysis degrades the elastic fiber network and collagen of the alveolar wall, the conserved module edge from Protease-Antiprotease Imbalance to Alveolar ECM and Elastin Destruction.
  evidence:
  - reference: PMID:42556749
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "oxidative stress-mediated activation of inflammatory signaling pathways such as nuclear factor-κB (NF-κB), mitogen-activated protein kinase (MAPK), and activator protein-1 (AP-1). These pathways contribute to the upregulation of MMP-2 expression and dysregulation of TIMP-2 activity, resulting in protease-antiprotease imbalance and progressive structural damage to the pulmonary extracellular matrix."
    explanation: This review establishes oxidative stress-driven MMP-2 upregulation and TIMP-2 dysregulation as central to protease-antiprotease imbalance in COPD pathogenesis and alveolar destruction.
  - reference: PMID:42556749
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "genetic polymorphisms in MMP-2 and TIMP-2 genes that may influence susceptibility to COPD and disease severity across different populations."
    explanation: Identifies genetic variation in the MMP-2/TIMP-2 axis as a determinant of COPD susceptibility and disease phenotype across populations.
- name: Cuproptosis-Driven Cell Death
  biological_scale: CELLULAR
  description: >-
    Proposed mechanism, advanced explicitly as a hypothesis by a 2026 review
    and not yet demonstrated directly in human COPD tissue. Cigarette smoke
    disrupts pulmonary copper homeostasis, creating a microenvironment
    permissive for cuproptosis — a copper-dependent regulated cell death driven
    by mitochondrial proteotoxic stress. Cuproptotic death of structural cells
    (alveolar epithelium and anti-inflammatory M2 macrophages) releases
    damage-associated molecular patterns (DAMPs) that fuel neutrophilic
    inflammation and pro-inflammatory macrophage polarization; that
    inflammatory milieu in turn impairs copper handling in surviving cells,
    which is the loop the review calls a self-sustaining metabolic-immune axis.
    Cellular metabolic dependency is proposed as the determinant of
    vulnerability: cells reliant on oxidative phosphorylation (alveolar type II
    epithelial cells, M2 macrophages) are predicted, not shown, to be
    exquisitely vulnerable.
  cell_types:
  - preferred_term: alveolar type II cell
    term:
      id: CL:0002063
      label: pulmonary alveolar type 2 cell
  - preferred_term: anti-inflammatory M2 macrophage
    term:
      id: CL:0000890
      label: M2 macrophage
  biological_processes:
  - preferred_term: copper homeostasis
    modifier: DYSREGULATED
    term:
      id: GO:0055070
      label: copper ion homeostasis
  - preferred_term: stress response to copper ion
    term:
      id: GO:1990169
      label: stress response to copper ion
  - preferred_term: cuproptosis
    term:
      id: GO:0160119
      label: cuproptosis
  - preferred_term: mitochondrial proteotoxic stress
    term:
      id: GO:0141164
      label: mitochondrial protein quality control
    description: >-
      Closest available binding for the mitochondrial proteotoxic stress the
      review names as the driver of cuproptosis. GO has no term for proteotoxic
      stress itself, so this names the machinery that stress acts on rather than
      the stress; a narrower term would be a new-term request.
  - preferred_term: oxidative phosphorylation
    term:
      id: GO:0006119
      label: oxidative phosphorylation
    description: >-
      Named as the metabolic dependency that is proposed to determine which
      cells are vulnerable, not as a process altered by this node.
  - preferred_term: inflammatory response
    modifier: INCREASED
    term:
      id: GO:0006954
      label: inflammatory response
  locations:
  - preferred_term: alveolus of lung
    term:
      id: UBERON:0002299
      label: alveolus of lung
  - preferred_term: bronchus
    term:
      id: UBERON:0002185
      label: bronchus
  downstream:
  - target: Chronic Inflammation
    hypothesis_groups:
    - emerging_cuproptosis_metabolic_immune_axis
    description: Cuproptotic DAMP release from dying epithelial cells and M2 macrophages amplifies neutrophilic recruitment and pro-inflammatory macrophage polarization, creating a vicious cycle of inflammation.
  notes: >-
    All therapeutic strategies (copper chelators, ionophores, nanoplatforms, PROTAC-based sensitizers) currently remain at preclinical or early exploratory stages with no clinical trials yet conducted in COPD, which is why none is curated under treatments. Cellular metabolic dependency is proposed as the determinant of vulnerability, and it is that dependency which the review uses to distinguish this mechanism from the other regulated cell death pathways in COPD. The paper explicitly distinguishes established evidence from speculative hypotheses in cuproptosis-based COPD therapeutics; see the emerging_cuproptosis_metabolic_immune_axis hypothesis grouping and the gap_copd_cuproptosis_direct_human_evidence discussion for how far the claims here are established.
  evidence:
  - reference: PMID:42604614
    reference_title: "Cuproptosis: The metabolic-immune axis in chronic obstructive pulmonary disease pathogenesis and therapeutics."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: cuproptosis functions not merely as a passive consequence but as a critical amplifier within a self-sustaining "Metabolic-Immune Cell Death Axis" that drives disease chronicity and progression
    explanation: Review proposes cuproptosis as a novel regulatory mechanism in COPD amplifying disease progression.
  - reference: PMID:42604614
    reference_title: "Cuproptosis: The metabolic-immune axis in chronic obstructive pulmonary disease pathogenesis and therapeutics."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: cigarette smoke actively disrupts pulmonary copper homeostasis
    explanation: Establishes cigarette smoke as the trigger for copper dysregulation in COPD pathogenesis.
  - reference: PMID:42604614
    reference_title: "Cuproptosis: The metabolic-immune axis in chronic obstructive pulmonary disease pathogenesis and therapeutics."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: cuproptotic death of structural cells releases immunogenic damage-associated molecular patterns (DAMPs) that fuel neutrophilic inflammation and pro-inflammatory macrophage polarization
    explanation: Describes DAMP-mediated amplification of inflammation as a consequence of cuproptotic cell death.
  - reference: PMID:42604614
    reference_title: "Cuproptosis: The metabolic-immune axis in chronic obstructive pulmonary disease pathogenesis and therapeutics."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: this inflammatory milieu further impairs copper handling in surviving cells, sensitizing them to subsequent death
    explanation: Identifies the self-sustaining cycle whereby inflammation impairs copper homeostasis and increases vulnerability to cuproptosis.
  - reference: PMID:42604614
    reference_title: "Cuproptosis: The metabolic-immune axis in chronic obstructive pulmonary disease pathogenesis and therapeutics."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: cells reliant on oxidative phosphorylation (such as alveolar type II epithelial cells and anti-inflammatory M2 macrophages) are predicted to be exquisitely vulnerable
    explanation: Establishes metabolic dependency (OXPHOS-reliance) as the cellular determinant of cuproptosis vulnerability in COPD.
phenotypes:
- category: Respiratory
  name: Dyspnea
  frequency: VERY_FREQUENT
  diagnostic: true
  evidence:
  - reference: PMID:28277858
    reference_title: "Pathophysiology of dyspnea in COPD."
    supports: SUPPORT
    snippet: Indeed, it is an important symptom in chronic obstructive pulmonary disease (COPD), where it is associated with limited physical activity, increased anxiety and depression, decreased health-related quality of life (HRQoL), and reduced survival.
    explanation: The literature supports that dyspnea is a common symptom in COPD and is frequently observed in patients, confirming its categorization as a respiratory phenotype with diagnostic importance.
  - reference: PMID:35698999
    reference_title: "The prevalence and assessment of pain and dyspnoea in acute exacerbations of COPD: A systematic review."
    supports: SUPPORT
    snippet: Dyspnoea and pain are symptoms of chronic obstructive pulmonary disease (COPD)... The pooled prevalence of pain and dyspnoea was 44% (95% confidence interval (CI) 35%-52%) and 91% (95% CI 87%-94%) respectively.
    explanation: This study highlights the high prevalence of dyspnea in patients with COPD, further supporting its status as a very frequent respiratory phenotype.
  - reference: PMID:34972922
    reference_title: "Exhaled Breath Condensate and Dyspnea in COPD."
    supports: SUPPORT
    snippet: Up to date research has shown a positive correlation between the elevated levels of some markers of EBC such as H2O2 and 8-isoprostane and dyspnea, while others present ambiguous results
    explanation: The correlation between dyspnea and COPD is reinforced by the positive association found with certain markers in exhaled breath condensate.
  sequelae:
  - target: Exercise Intolerance
  phenotype_term:
    preferred_term: Dyspnea
    term:
      id: HP:0002094
      label: Dyspnea
- category: Respiratory
  name: Chronic Cough
  frequency: VERY_FREQUENT
  diagnostic: true
  evidence:
  - reference: PMID:29881269
    reference_title: "Chronic cough as a novel phenotype of chronic obstructive pulmonary disease."
    supports: SUPPORT
    snippet: Compared with patients without chronic cough, those with chronic cough exhibited a lower forced expiratory volume in 1 second (% predicted) and diffusing capacity of the lungs for carbon monoxide (% predicted), more frequent AECOPD, more severe dyspnea, and worse QoL.
    explanation: The study identifies chronic cough as a common and significant phenotype in COPD patients, indicating its very frequent occurrence and diagnostic importance.
  - reference: PMID:31740261
    reference_title: "\"Chronic obstructive pulmonary disease and phenotypes: a state-of-the-art.\"."
    supports: SUPPORT
    snippet: COPD is now widely accepted as a heterogeneous condition with multiple phenotypes and endotypes. This review will discuss the old and new concepts for the different types of COPD phenotypes.
    explanation: The statement mentions the heterogeneity of COPD with multiple phenotypes, which could include phenotypes like chronic cough.
  notes: Often productive of mucus
  phenotype_term:
    preferred_term: Chronic Cough
    term:
      id: HP:0034315
      label: Chronic cough
- category: Respiratory
  name: Sputum Production
  frequency: VERY_FREQUENT
  evidence:
  - reference: PMID:22753831
    reference_title: "Chronic cough and sputum production: a clinical COPD phenotype?"
    supports: SUPPORT
    snippet: 'Chronic cough and sputum production: a clinical COPD phenotype?'
    explanation: The title of the article itself suggests that sputum production is recognized as a phenotype of COPD.
  - reference: PMID:23204254
    reference_title: "Chronic bronchitis and chronic obstructive pulmonary disease."
    supports: SUPPORT
    snippet: Chronic bronchitis (CB) is a common but variable phenomenon in chronic obstructive pulmonary disease (COPD).
    explanation: Chronic bronchitis, which involves overproduction and hypersecretion of mucus, is described as a common phenomenon in COPD, indicating sputum production is a frequent COPD phenotype.
  notes: Mucus is often difficult to expectorate
  phenotype_term:
    preferred_term: Sputum Production
    term:
      id: HP:0033709
      label: Increased sputum production
- category: Respiratory
  frequency: FREQUENT
  name: Wheezing
  notes: Due to airflow obstruction
  evidence:
  - reference: PMID:33302722
    reference_title: "Is the Symptom of Cough in Chronic Obstructive Pulmonary Disease Important?"
    supports: SUPPORT
    snippet: The clinical symptoms of this disease include progressive dyspnea, cough, expectoration, and wheezing, among others.
    explanation: The abstract mentions wheezing as one of the clinical symptoms of Chronic Obstructive Pulmonary Disease (COPD).
  - reference: PMID:11963614
    reference_title: "Breathless."
    supports: SUPPORT
    snippet: Remember, all that wheezes is not asthma; therefore, providers in this case had to determine if the patient was suffering something such as anaphylaxis, asthma, bronchitis, pneumonia or even congestive heart failure (CHF).
    explanation: The abstract indicates that wheezing can be a symptom of various conditions, including COPD-related bronchospasm.
  - reference: PMID:2404712
    reference_title: "Pathology of chronic airflow obstruction."
    supports: SUPPORT
    snippet: Increased airways reactivity is present in 15 to 70 percent of patients with chronic airflow obstruction.
    explanation: The abstract discusses increased airway reactivity, which is related to wheezing, in patients with chronic airflow obstruction, including COPD.
  phenotype_term:
    preferred_term: Wheezing
    term:
      id: HP:0030828
      label: Wheezing
- category: Respiratory
  frequency: OCCASIONAL
  name: Barrel Chest
  phenotype_term:
    preferred_term: Barrel Chest
    term:
      id: HP:0001552
      label: Barrel-shaped chest
  notes: Due to hyperinflation of the lungs
  evidence:
  - reference: PMID:25159007
    reference_title: "Lung hyperinflation in chronic obstructive pulmonary disease: mechanisms, clinical implications and treatment."
    supports: SUPPORT
    snippet: Lung hyperinflation is highly prevalent in patients with chronic obstructive pulmonary disease and occurs across the continuum of the disease.
    explanation: The reference supports the association of lung hyperinflation with COPD but does not specifically mention 'Barrel Chest' or its frequency.
  - reference: PMID:34972922
    reference_title: "Exhaled Breath Condensate and Dyspnea in COPD."
    supports: SUPPORT
    snippet: Attempts to connect the products of the analysis of the EBC with the clinical manifestations of COPD such as dyspnea are scarce.
    explanation: The reference discusses the clinical manifestations of COPD but does not specifically mention 'Barrel Chest' or its frequency.
  - reference: PMID:23204254
    reference_title: "Chronic bronchitis and chronic obstructive pulmonary disease."
    supports: NO_EVIDENCE
    snippet: Chronic bronchitis (CB) is a common but variable phenomenon in chronic obstructive pulmonary disease (COPD).
    explanation: The reference discusses chronic bronchitis in COPD but does not mention 'Barrel Chest' or its frequency.
- category: Respiratory
  frequency: OCCASIONAL
  name: Respiratory Failure
  sequelae:
  - target: Hypoxemia
  - target: Hypercapnia
  evidence:
  - reference: PMID:14621114
    reference_title: "Respiratory failure in chronic obstructive pulmonary disease."
    supports: REFUTE
    snippet: Respiratory failure is still an important complication of chronic obstructive pulmonary disease (COPD) and hospitalisation with an acute episode being a poor prognostic marker.
    explanation: The reference indicates that respiratory failure is an important and common complication of COPD, not an occasional one.
  - reference: PMID:38692758
    reference_title: "Targeting Hypercapnia in Chronic Lung Disease and Obesity Hypoventilation: Benefits and Challenges."
    supports: REFUTE
    snippet: Hypoventilation is a complication that is not uncommon in chronic obstructive pulmonary disease and calls for both medical treatment of the underlying disease and, frequently, noninvasive ventilation either during exacerbations requiring hospitalization or in a chronic state in the patient at home.
    explanation: The reference suggests that hypoventilation, which can lead to respiratory failure, is not uncommon in COPD.
  phenotype_term:
    preferred_term: Respiratory Failure
    term:
      id: HP:0002878
      label: Respiratory failure
- category: Systemic
  frequency: FREQUENT
  name: Fatigue
  evidence:
  - reference: PMID:33998496
    reference_title: "Fatigue: A neglected symptom of COPD."
    supports: SUPPORT
    snippet: 'Fatigue: A neglected symptom of COPD.'
    explanation: The title itself indicates that fatigue is a recognized symptom of COPD.
  - reference: PMID:31729154
    reference_title: "Fatigue and health-related quality of life among patients with chronic obstructive pulmonary disease in China."
    supports: SUPPORT
    snippet: Fatigue is an important yet ignored symptom of chronic obstructive pulmonary disease (COPD).
    explanation: This reference acknowledges fatigue as an important symptom of COPD, supporting its frequent occurrence.
  - reference: PMID:24874124
    reference_title: "The systemic nature of chronic lung disease."
    supports: SUPPORT
    snippet: Symptoms in COPD do not solely arise from the degree of airflow obstruction as exercise limitation is compounded by the specific secondary manifestations of the disease including skeletal muscle impairment, osteoporosis, mood disturbance, anemia, and hormonal imbalance.
    explanation: While this reference does not mention fatigue explicitly, it discusses systemic manifestations of COPD, implying the systemic nature of the disease.
  phenotype_term:
    preferred_term: Fatigue
    term:
      id: HP:0012378
      label: Fatigue
- category: Systemic
  frequency: OCCASIONAL
  name: Weight Loss
  notes: More common in advanced disease
  evidence:
  - reference: PMID:12406664
    reference_title: "Weight loss in chronic obstructive pulmonary disease. Mechanisms and implications."
    supports: SUPPORT
    snippet: Weight loss occurs frequently in patients with chronic obstructive pulmonary disease (COPD).
    explanation: The literature states that weight loss is a common phenomenon in COPD patients, which supports the statement that weight loss is a systemic issue in COPD, more common in advanced disease.
  - reference: PMID:18415812
    reference_title: "COPD as a systemic disease."
    supports: SUPPORT
    snippet: These include unintentional weight loss, skeletal muscle dysfunction, an increased risk of cardiovascular disease, osteoporosis, and depression, among others.
    explanation: This reference mentions unintentional weight loss as one of the systemic effects of COPD, supporting the statement.
  - reference: PMID:36922031
    reference_title: "Contemporary Concise Review 2022: Chronic obstructive pulmonary disease."
    supports: SUPPORT
    snippet: COPD patients with psychological (high anxiety and depression) and cachectic (underweight and osteoporotic) comorbidity have higher mortality and exacerbate more.
    explanation: The mention of cachexia (underweight) as a comorbidity in COPD patients aligns with the statement about weight loss being more common in advanced disease.
  phenotype_term:
    preferred_term: Weight loss
    term:
      id: HP:0001824
      label: Weight loss
- category: Cardiovascular
  name: Exercise Intolerance
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Exercise Intolerance
    term:
      id: HP:0003546
      label: Exercise intolerance
- category: Respiratory
  name: Hypoxemia
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Hypoxemia
    term:
      id: HP:0012418
      label: Hypoxemia
- category: Respiratory
  name: Hypercapnia
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Hypercapnia
    term:
      id: HP:0012416
      label: Hypercapnia
biochemical:
- name: Arterial Blood Gases
  presence: Altered
  notes: May show hypoxemia and hypercapnia.
  evidence:
  - reference: PMID:21812941
    reference_title: "Explained variance for blood gases in a population with COPD."
    supports: SUPPORT
    snippet: The aim of this study was to identify predictors of hypoxemia, hypercapnia and increased alveolar-arterial oxygen difference in COPD patients.
    explanation: The study confirms that COPD patients may show hypoxemia and hypercapnia, but it focuses on the predictors rather than just the presence of these conditions.
  - reference: PMID:34756790
    reference_title: "Arterial Blood Gas and Rotational Thromboelastometry Parameters in Healthy Rescuers Incidentally Exposed to Nitroglycerin, Nitrogen Compounds, and Combustion Products."
    supports: SUPPORT
    snippet: Respiratory acidosis with hypoxia, hypercapnia, a compensatory metabolic response, and mild hyperfibrinolysis were probably related to the combined effect of nitrogen compounds and the inhaled toxic products of detonation.
    explanation: The study discusses the occurrence of hypoxia and hypercapnia in specific exposure situations, including COPD contexts.
  - reference: PMID:25119324
    reference_title: "Arterialised earlobe capillary blood gases in the COPD population."
    supports: SUPPORT
    snippet: The prevalence of this sampling method has grown among health professionals, coupled with a growing demand for domiciliary oxygen therapy in the UK, in particular for those who have chronic obstructive pulmonary disease (COPD).
    explanation: While this does not directly confirm hypoxemia and hypercapnia, it suggests the necessity of oxygen therapy for COPD patients, implying altered arterial blood gases.
  - reference: PMID:18044093
    reference_title: "Respiratory disorders during sleep in chronic obstructive pulmonary disease."
    supports: SUPPORT
    snippet: Patients with COPD may show slow, progressive deteriorations in arterial blood gases during the night, particularly during rapid eye movement (REM) sleep. This is mainly due to hypoventilation... The severity of gas exchanges alterations is proportional to the degree of impairment of diurnal pulmonary function tests, particularly of partial pressure of oxygen (PaO2) and of carbon dioxide (PaCO2) in arterial blood...
    explanation: This reference strongly supports the statement by highlighting altered arterial blood gases in COPD due to hypoventilation during sleep.
- name: C-Reactive Protein (CRP)
  presence: Elevated
  context: General inflammation and exacerbations.
  evidence:
  - reference: PMID:23206444
    reference_title: "Association between C-reactive protein concentration and chronic obstructive pulmonary disease: a systematic review and meta-analysis."
    supports: SUPPORT
    snippet: Patients with COPD had higher serum CRP concentrations than healthy controls (WMD 4.72 mg/l, 95% CI 2.98, 6.47).
    explanation: This meta-analysis suggests that patients with stable COPD had higher serum CRP concentrations than healthy controls, indicating elevated CRP in general inflammation related to COPD.
  - reference: PMID:24313775
    reference_title: "Biomarkers that predict and guide therapy for exacerbations of chronic obstructive pulmonary disease."
    supports: SUPPORT
    snippet: These biomarkers include C-reactive protein, procalcitonin, and peripheral blood eosinophil count, which are readily available.
    explanation: The study identifies CRP as an important biomarker in COPD exacerbations, indicating its elevation in such contexts.
  - reference: PMID:24102428
    reference_title: "Serum angiopoietin-2 and CRP levels during COPD exacerbations."
    supports: SUPPORT
    snippet: Serum CRP levels were also significantly higher on D1 compared to D7 (p < 0.001).
    explanation: The findings that CRP levels are elevated at the onset of COPD exacerbations support the statement.
  - reference: PMID:26595735
    reference_title: "Immune Dysfunction in Patients with Chronic Obstructive Pulmonary Disease."
    supports: SUPPORT
    snippet: A number of studies support the conclusion that immune dysfunction leads to exacerbations and disease severity in COPD.
    explanation: The chronic inflammation involving immune dysfunction and exacerbations in COPD is associated with elevated CRP, supporting the statement.
  - reference: PMID:37082823
    reference_title: "Inflammation biomarkers in OSA, chronic obstructive pulmonary disease, and chronic obstructive pulmonary disease/OSA overlap syndrome."
    supports: SUPPORT
    snippet: Levels of interleukin 6 (IL-6), high-sensitivity C-reactive protein (hs-CRP), and granulocyte colony stimulating factor (G-CSF) were higher in participants with OVS and COPD compared with healthy controls and participants with OSA.
    explanation: Elevated hs-CRP in COPD patients relative to healthy controls supports the general inflammation and exacerbation context.
- name: Forced Expiratory Volume in 1 Second (FEV1)
  presence: Reduced, with a low post-bronchodilator FEV1/FVC ratio confirming persistent airflow limitation; partially reversible or more slowly declining with bronchodilator and anti-inflammatory therapy.
  context: >-
    Spirometric pulmonary function measure (percent of predicted FEV1, together
    with the FEV1/FVC ratio) used to diagnose COPD, grade severity of airflow
    limitation, monitor disease progression, and assess pharmacodynamic response
    to bronchodilator and anti-inflammatory therapy. FEV1 is recognized by the
    FDA as a validated surrogate endpoint supporting traditional approval of COPD
    drugs.
  biomarker_term:
    preferred_term: Forced Expiratory Volume in 1 Second (FEV1)
    term:
      id: NCIT:C38084
      label: Forced Expiratory Volume in 1 Second
  synonyms:
  - FEV1
  - percent predicted FEV1
  - FEV1/FVC ratio
  readouts:
  - target: Airflow Limitation
    relationship: PHARMACODYNAMIC_MARKER_OF
    direction: NEGATIVE
    endpoint_context: PHARMACODYNAMIC
    regulatory_endpoint_refs:
    - FDA-SE-adult-noncancer-013
    interpretation: >-
      Higher or less-declining percent-predicted FEV1 indicates reduced airflow
      limitation; treatment-induced improvement in FEV1 reports the
      pharmacodynamic response to bronchodilator and anti-inflammatory therapy
      and underpins the FDA surrogate-endpoint basis for traditional approval of
      COPD drugs.
    evidence:
    - reference: PMID:19716960
      reference_title: "Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Primary endpoints were change in prebronchodilator forced expiratory volume in 1 s (FEV(1)) and the rate of exacerbations that were moderate (glucocorticosteroid-treated) or severe."
      explanation: >-
        The pivotal placebo-controlled trials of the phosphodiesterase-4
        inhibitor roflumilast used change in prebronchodilator FEV1 as a primary
        endpoint, establishing FEV1 as a regulatory efficacy readout for COPD
        drug approval.
    - reference: PMID:19716960
      reference_title: "Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "In a pooled analysis, prebronchodilator FEV(1) increased by 48 mL with roflumilast compared with placebo (p<0.0001)."
      explanation: >-
        FEV1 improved measurably with anti-inflammatory therapy versus placebo,
        confirming FEV1 as a treatment-responsive pharmacodynamic marker of
        airflow limitation in COPD.
  evidence:
  - reference: PMID:18836213
    reference_title: "A 4-year trial of tiotropium in chronic obstructive pulmonary disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The patients were at least 40 years of age, with a forced expiratory volume in 1 second (FEV(1)) of 70% or less after bronchodilation and a ratio of FEV(1) to forced vital capacity (FVC) of 70% or less."
    explanation: >-
      Reduced FEV1 and a low FEV1/FVC ratio are the spirometric criteria used to
      define and grade airflow limitation in COPD, supporting FEV1 as the core
      monitoring and severity biomarker.
genetic:
- name: SERPINA1
  gene_term:
    preferred_term: SERPINA1
    term:
      id: hgnc:8941
      label: SERPINA1
  association: Alpha-1 antitrypsin deficiency is the most common genetic cause of COPD.
  notes: Encodes alpha-1 antitrypsin (AAT); deficiency leads to protease-antiprotease imbalance and emphysema.
  evidence:
  - reference: PMID:32800189
    reference_title: "Alpha-1 Antitrypsin Deficiency Associated COPD."
    supports: SUPPORT
    snippet: Alpha-1 antitrypsin deficiency (AATD) was the first genetic risk factor for chronic obstructive pulmonary disease (COPD) described.
    explanation: The abstract clearly mentions that AATD is a genetic risk factor for COPD, supporting the statement.
  - reference: PMID:35104244
    reference_title: "Ferret models of alpha-1 antitrypsin deficiency develop lung and liver disease."
    supports: SUPPORT
    snippet: Alpha-1 antitrypsin deficiency (AATD) is the most common genetic cause and risk factor for chronic obstructive pulmonary disease.
    explanation: The text directly supports the statement by identifying AATD as a common genetic cause and risk factor for COPD.
  - reference: PMID:36630963
    reference_title: "Capturing the conversion of the pathogenic alpha-1-antitrypsin fold by ATF6 enhanced proteostasis."
    supports: SUPPORT
    snippet: Genetic variation in alpha-1 antitrypsin (AAT) causes AAT deficiency (AATD) through liver aggregation-associated gain-of-toxic pathology and/or insufficient AAT activity in the lung manifesting as chronic obstructive pulmonary disease (COPD).
    explanation: The abstract highlights that genetic variation in AAT leading to AATD manifests as COPD, thus supporting the statement.
- name: MMP12
  gene_term:
    preferred_term: MMP12
    term:
      id: hgnc:7158
      label: MMP12
  association: Matrix metalloproteinase-12 contributes to emphysema development.
  notes: Macrophage-derived protease that degrades elastin and extracellular matrix.
- name: NLRP3
  gene_term:
    preferred_term: NLRP3
    term:
      id: hgnc:16400
      label: NLRP3
  association: Inflammasome activation contributes to chronic inflammation.
  notes: Activated by mitochondrial ROS and particulate exposures, leading to IL-1β and IL-18 release.
- name: TNF
  gene_term:
    preferred_term: TNF
    term:
      id: hgnc:11892
      label: TNF
  association: Tumor necrosis factor mediates systemic and airway inflammation.
  notes: Key pro-inflammatory cytokine in COPD pathogenesis.
- name: IL1B
  gene_term:
    preferred_term: IL1B
    term:
      id: hgnc:5992
      label: IL1B
  association: Interleukin-1 beta drives inflammatory signaling.
  notes: Product of NLRP3 inflammasome activation.
- name: IL6
  gene_term:
    preferred_term: IL6
    term:
      id: hgnc:6018
      label: IL6
  association: Interleukin-6 contributes to systemic inflammation.
  notes: Elevated in serum and associated with COPD comorbidities.
- name: NFE2L2
  gene_term:
    preferred_term: NFE2L2
    term:
      id: hgnc:7782
      label: NFE2L2
  association: Nrf2 transcription factor regulates antioxidant defense.
  notes: Reduced activity impairs response to oxidative stress in COPD.
environmental:
- name: Smoking
  influences_mechanisms:
  - target: Chronic Inflammation
    environmental_effect: TRIGGERS
    causal_link_type: DIRECT
    description: >-
      Inhaled smoke is the irritant this node names by name, and it meets the
      airway epithelium with nothing in between, which is what makes the link
      direct. Both items are graded partial because each reports risk of the
      disease rather than a measurement of airway inflammation, and the second
      is carried precisely because it limits the claim: most smokers never
      develop the disease, so the exposure is not sufficient.
    evidence:
    - reference: PMID:28933915
      reference_title: "Airway Epithelial Barrier Dysfunction in Chronic Obstructive Pulmonary Disease: Role of Cigarette Smoke Exposure."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "The epithelial lining of the airway forms the first barrier against environmental insults, such as inhaled cigarette smoke, which is the primary risk factor for the development of chronic obstructive pulmonary disease (COPD)."
      explanation: >-
        Names inhaled cigarette smoke as the environmental insult the airway
        epithelium meets first, and as the primary risk factor for developing
        the disease. The epithelial barrier is where this node begins.
    - reference: PMID:30810540
      reference_title: "ROLE OF GENETIC SUSCEPTIBILITY IN NICOTINE ADDICTION AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "Although cigarette smoking is the major risk factor, only 10-20% of smokers develop COPD."
      explanation: >-
        Records that only 10 to 20 percent of smokers develop the disease.
        Carried deliberately, because it bounds what this link can be read to
        claim.
  - target: Cuproptosis-Driven Cell Death
    environmental_effect: TRIGGERS
    causal_link_type: DIRECT
    description: >-
      The review names inhaled smoke as what disrupts pulmonary copper
      homeostasis and so makes the microenvironment permissive for cuproptosis,
      which is the initiating step of the proposed metabolic-immune axis. Wired
      as an explicit link because the node otherwise has no upstream and its
      trigger would exist only as prose. The cited claim is that smoke disrupts
      copper handling, not that it has been shown to cause cuproptotic death in
      human airway tissue.
    evidence:
    - reference: PMID:42604614
      reference_title: "Cuproptosis: The metabolic-immune axis in chronic obstructive pulmonary disease pathogenesis and therapeutics."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: cigarette smoke actively disrupts pulmonary copper homeostasis
      explanation: >-
        Names the exposure as the cause of the copper dysregulation this node
        begins from.
  notes: Primary risk factor for development and progression.
  evidence:
  - reference: PMID:30810540
    reference_title: "ROLE OF GENETIC SUSCEPTIBILITY IN NICOTINE ADDICTION AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE."
    supports: SUPPORT
    snippet: Although cigarette smoking is the major risk factor, only 10-20% of smokers develop COPD.
    explanation: This clearly identifies smoking as a major risk factor for COPD development.
  - reference: PMID:31759959
    reference_title: "Cardiovascular Risk in COPD: Deciphering the Contribution of Tobacco Smoking."
    supports: SUPPORT
    snippet: The observation that COPD is an independent risk factor for cardiovascular disease (CVDs) comes from comparisons between smokers with COPD and smokers without COPD.
    explanation: This snippet highlights the relationship between smoking, COPD, and other health issues, indirectly supporting smoking as a risk factor for COPD.
  - reference: PMID:28933915
    reference_title: "Airway Epithelial Barrier Dysfunction in Chronic Obstructive Pulmonary Disease: Role of Cigarette Smoke Exposure."
    supports: SUPPORT
    snippet: The epithelial lining of the airway forms the first barrier against environmental insults, such as inhaled cigarette smoke, which is the primary risk factor for the development of chronic obstructive pulmonary disease (COPD).
    explanation: Directly states that cigarette smoke is the primary risk factor for COPD development.
  - reference: PMID:18303418
    reference_title: "Smoking: relationship to chronic bronchitis, chronic obstructive pulmonary disease and mortality."
    supports: SUPPORT
    snippet: Approximately one-quarter of smokers can be affected by clinically significant chronic obstructive pulmonary disease. ... Smokers may reduce their risk of developing chronic obstructive pulmonary disease by physical activity and increase their survival by smoking reduction.
    explanation: This supports the statement by highlighting the prevalence of COPD among smokers and the role of smoking in disease progression.
  - reference: PMID:37429033
    reference_title: "Age of Initiating Smoking: An Independent Predictor of Chronic Obstructive Pulmonary Disease in Later Life."
    supports: SUPPORT
    snippet: 'Age of Initiating Smoking: An Independent Predictor of Chronic Obstructive Pulmonary Disease in Later Life.'
    explanation: This implies that smoking is a risk factor in the development of COPD.
  exposure_term:
    preferred_term: Tobacco smoking exposure
    term:
      id: ECTO:6000029
      label: exposure to tobacco smoking
- name: Air Pollution
  influences_mechanisms:
  - target: Oxidative Stress and Mitochondrial Dysfunction
    environmental_effect: EXACERBATES
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      Inhaled pollutants are named at this node alongside cigarette smoke as
      drivers of mitochondrial reactive oxygen species. Recorded as
      exacerbating rather than triggering because both cited studies measure
      effects on respiratory health rather than initiation, and the
      intermediates are left unknown because neither measures an oxidative or
      mitochondrial marker. Worth stating plainly, because the smoking link
      into the inflammation node was graded from node wording rather than from
      evidence: this node's own text uses the word trigger for pollutants, and
      would on its face have supported a triggering grade here too. It is not
      taken, because that verb describes what pollutants do to reactive oxygen
      species production once inhaled, not whether the exposure starts the
      disease, and on that question the entry's own note and both cited
      studies say the same thing, that pollution worsens established disease.
      The entry does hold a paper on oxidant and antioxidant balance, but its
      quotable sentence names oxidative stress without naming pollution, so it
      cannot carry an exposure-to-node claim and is not cited here.
    evidence:
    - reference: PMID:16916323
      reference_title: "Epidemiology of chronic obstructive pulmonary disease: health effects of air pollution."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "Evidence from epidemiological studies finding consistent associations between air pollution and various outcomes (respiratory symptoms, reduced lung function, chronic bronchitis and mortality), has suggested that outdoor air pollution is a contributing cause of morbidity and mortality."
      explanation: >-
        Epidemiological synthesis finding consistent associations between air
        pollution and respiratory symptoms, reduced lung function, chronic
        bronchitis, and mortality. It reaches health outcomes, not the
        oxidative step this node holds.
    - reference: PMID:33542053
      reference_title: "Personal exposure to air pollution and respiratory health of COPD patients in London."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Our findings suggest that, when considering total personal exposure to air pollutants, mainly the gaseous pollutants affect COPD patients' health."
      explanation: >-
        Personal-exposure measurements in patients who already have the
        disease, which is the design that fits an exacerbating grade. It
        reports effects on patient health rather than on this node.
  notes: Exposure to pollutants can exacerbate symptoms.
  evidence:
  - reference: PMID:33542053
    reference_title: "Personal exposure to air pollution and respiratory health of COPD patients in London."
    supports: SUPPORT
    snippet: Our findings suggest that, when considering total personal exposure to air pollutants, mainly the gaseous pollutants affect COPD patients' health.
    explanation: This study found that exposure to various air pollutants adversely affects the health of COPD patients, supporting the idea that air pollution exacerbates COPD symptoms.
  - reference: PMID:25673984
    reference_title: "COPD: balancing oxidants and antioxidants."
    supports: SUPPORT
    snippet: The major pathogenic factors causing disease include infection and inflammation, protease and antiprotease imbalance, and oxidative stress overwhelming antioxidant defenses.
    explanation: This reference discusses environmental factors, including pollutants, that contribute to oxidative stress and inflammation in COPD, thus supporting the statement.
  - reference: PMID:37068517
    reference_title: "Chronic Obstructive Pulmonary Disease and Work: The Continuing Narrative."
    supports: SUPPORT
    snippet: Harmful inhaled workplace exposures can contribute to the development of chronic obstructive pulmonary disease (COPD).
    explanation: This statement supports the environmental influence on COPD, including air pollutants, as a risk factor.
  - reference: PMID:16916323
    reference_title: "Epidemiology of chronic obstructive pulmonary disease: health effects of air pollution."
    supports: SUPPORT
    snippet: Evidence from epidemiological studies finding consistent associations between air pollution and various outcomes (respiratory symptoms, reduced lung function, chronic bronchitis and mortality), has suggested that outdoor air pollution is a contributing cause of morbidity and mortality.
    explanation: This reference directly links air pollution to exacerbation and pathogenesis of COPD, supporting the statement.
  - reference: PMID:27751401
    reference_title: "Impact of air pollution on the burden of chronic respiratory diseases in China: time for urgent action."
    supports: SUPPORT
    snippet: We focus on the major constituents of air pollutants and their impacts on chronic respiratory diseases.
    explanation: This review highlights the detrimental effects of air pollution on respiratory health, particularly in the discussion on chronic respiratory diseases such as COPD.
  exposure_term:
    preferred_term: Air pollution exposure
    term:
      id: ECTO:8000036
      label: exposure to air pollution
- name: Occupational Dust and Chemicals
  influences_mechanisms:
  - target: Chronic Inflammation
    environmental_effect: PREDISPOSES
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      Workplace dusts, gases, and chemicals are an established route to the
      disease, but unlike cigarette smoke they are not named at this node and
      no cited sentence follows them as far as airway inflammation. Graded
      below the smoking link into this same node for that reason.
    evidence:
    - reference: PMID:11964759
      reference_title: "Chronic obstructive lung diseases and occupational exposure."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "occupational exposure to dusts, chemicals and gases will be considered an established, or supported by good evidence, risk factor for chronic obstructive pulmonary disease"
      explanation: >-
        States that occupational exposure to dusts, chemicals, and gases is an
        established risk factor supported by good evidence. The sentence
        reaches the disease, not this node.
  notes: Long-term exposure increases risk.
  evidence:
  - reference: PMID:11964759
    reference_title: "Chronic obstructive lung diseases and occupational exposure."
    supports: SUPPORT
    snippet: occupational exposure to dusts, chemicals and gases will be considered an established, or supported by good evidence, risk factor for chronic obstructive pulmonary disease
    explanation: The abstract confirms that occupational exposure to dusts, chemicals, and gases is a well-supported risk factor for chronic obstructive pulmonary disease.
  - reference: PMID:20535848
    reference_title: "Lung function loss associated with occupational dust exposure in metal smelting."
    supports: SUPPORT
    snippet: Lung function loss associated with occupational dust exposure in metal smelting
    explanation: This study provides evidence of lung function loss due to occupational dust exposure, supporting the assertion that long-term exposure to such environmental factors increases the risk of chronic obstructive pulmonary disease.
  - reference: PMID:23361196
    reference_title: "Long-term respiratory health effects in textile workers."
    supports: SUPPORT
    snippet: Recent studies have recognized the contribution of workplace exposures to chronic lung diseases, in particular chronic obstructive pulmonary disease (COPD)
    explanation: The abstract discusses the recognized contribution of workplace exposures, including textile dust, to chronic obstructive pulmonary disease.
  - reference: PMID:24278358
    reference_title: "Biopersistent granular dust and chronic obstructive pulmonary disease: a systematic review and meta-analysis."
    supports: SUPPORT
    snippet: Occupational inhalative exposure to bg-dust was associated with a statistically significant decreased FEV1 and FEV1/FVC revealing airway obstruction consistent with COPD
    explanation: The meta-analysis presented indicates a significant association between occupational exposure to inorganic dust and the development of chronic obstructive pulmonary disease.
  - reference: PMID:35409627
    reference_title: "Environmental Substances Associated with Chronic Obstructive Pulmonary Disease-A Scoping Review."
    supports: SUPPORT
    snippet: Pesticides in general and especially organophosphate and carbamate insecticides... showed an association, and cadmium (Cd), chromium (Cr and CrVI), arsenic (As), and diisocyanates, a possible association with COPD
    explanation: The scoping review identifies several environmental substances, including chemicals associated with occupational exposure, that have a strong or possible association with chronic obstructive pulmonary disease.
  exposure_term:
    preferred_term: Occupational dust exposure
    term:
      id: ECTO:7000001
      label: exposure to dust
treatments:
- name: Smoking Cessation
  description: Stopping smoking to slow disease progression and improve outcomes.
  evidence:
  - reference: PMID:25496790
    reference_title: "[Smoking cessation in smokers with chronic obstructive pulmonary disease]."
    supports: SUPPORT
    snippet: Stopping smoking reduces the risk of developing COPD and is an essential treatment for this inflammatory disease. Smoking cessation decreases the prevalence of respiratory symptoms, number of hospitalizations, and decline in FEV1, as well as exacerbation frequency and overall mortality.
    explanation: The reference clearly states that smoking cessation is essential in reducing various harmful outcomes related to COPD.
  - reference: PMID:19811377
    reference_title: "Defining disease modification in chronic obstructive pulmonary disease."
    supports: SUPPORT
    snippet: Smoking cessation and lung volume reduction surgery would both qualify as disease-modifying interventions.
    explanation: The reference identifies smoking cessation as a disease-modifying intervention, which indicates its importance in slowing disease progression and thus improving outcomes.
  - reference: PMID:11935838
    reference_title: "Minimizing the impact of chronic obstructive pulmonary disease."
    supports: SUPPORT
    snippet: The most important intervention is smoking cessation.
    explanation: The reference emphasizes that smoking cessation is the most important intervention to minimize the impact of COPD.
  - reference: PMID:27576232
    reference_title: "Respiratory Conditions Update: Chronic Obstructive Pulmonary Disease."
    supports: SUPPORT
    snippet: Smoking cessation is the only intervention shown to slow disease progression.
    explanation: The reference clearly supports the claim that smoking cessation can slow disease progression and improve outcomes for COPD patients.
  therapeutic_modality: BEHAVIORAL
  treatment_term:
    preferred_term: behavioral counseling
    term:
      id: NCIT:C181743
      label: Behavioral Counseling
- name: Bronchodilators
  description: Medications that relax muscles of the airways to improve airflow (e.g., beta-agonists, anticholinergics).
  evidence:
  - reference: PMID:29794201
    reference_title: "Clinical Pharmacology of Bronchodilator Medications."
    supports: SUPPORT
    snippet: Bronchodilator therapy can often decrease symptoms of air-flow obstruction by relaxing airway smooth muscle (bronchodilation), decreasing dyspnea, and improving quality of life.
    explanation: The reference discusses how bronchodilator therapy relaxes airway smooth muscle, which improves airflow in obstructive lung diseases like COPD.
  - reference: PMID:27576232
    reference_title: "Respiratory Conditions Update: Chronic Obstructive Pulmonary Disease."
    supports: SUPPORT
    snippet: Long-acting beta2-agonists and long-acting muscarinic antagonists are first-line treatments for patients with persistently symptomatic COPD with an FEV1 of 80% or less of predicted.
    explanation: This reference identifies bronchodilators, specifically long-acting beta2-agonists and muscarinic antagonists, as key treatments for COPD by improving airflow.
  - reference: PMID:28757318
    reference_title: "New Treatment Option for Chronic Obstructive Pulmonary Disease: Two Long-Acting Bronchodilators in a Single Metered-Dose Inhaler."
    supports: SUPPORT
    snippet: Combination long-acting inhaled bronchodilators are central to the management of patients with moderate to very severe chronic obstructive pulmonary disease.
    explanation: This reference confirms that bronchodilators, such as long-acting beta2 agonists and long-acting muscarinic antagonists, are used to manage COPD symptoms by improving pulmonary function.
  - reference: PMID:41198528
    reference_title: "Update 2025 of the Spanish COPD Guidelines (GesEPOC): Pharmacological Treatment of Stable COPD."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "The cornerstone of COPD treatment is long-acting bronchodilators, either as monotherapy or in combination, depending on the patient's risk level."
    explanation: The 2025 GesEPOC pharmacological-treatment guideline establishes long-acting bronchodilators as the cornerstone of stable COPD treatment.
  treatment_term:
    preferred_term: bronchodilator therapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: bronchodilator
      term:
        id: NCIT:C319
        label: Bronchodilator
- name: Inhaled Corticosteroids
  description: Reduce airway inflammation and frequency of exacerbations.
  evidence:
  - reference: PMID:20102305
    reference_title: "Inhaled corticosteroids in chronic obstructive pulmonary disease: a review."
    supports: SUPPORT
    snippet: Short-term treatment with ICS improves lung function and quality of life; in addition, several studies with longer follow-up have shown less decline over time in quality of life, and fewer exacerbations. By contrast, long-term studies have been unable to show substantial improvement in the decline of lung function in COPD.
    explanation: While ICS do help reduce the frequency of exacerbations and improve quality of life, the evidence on their effectiveness in reducing airway inflammation specifically is more nuanced.
  - reference: PMID:37348121
    reference_title: "Targeting Type 2 Inflammation and Epithelial Alarmins in Chronic Obstructive Pulmonary Disease: A Biologics Outlook."
    supports: SUPPORT
    snippet: Current pharmacologic strategies, including first- and second-line therapies such as long-acting β2-agonists, long-acting muscarinic antagonists, inhaled corticosteroids, phosphodiesterase-4 inhibitors, and macrolides, provide relief to patients with COPD
    explanation: ICS are included in the treatment strategies, and while they help mitigate exacerbations, the snippet suggests that not all patients experience reduced airway inflammation.
  - reference: PMID:29938633
    reference_title: "[Treatment of stable chronic obstructive pulmonary disease]."
    supports: SUPPORT
    snippet: The major alteration has been in the section concerning treatment with inhalation medication - now aiming at an easy stepwise up-titration of long-acting medicine as well as a guide of how to down-titrate inhaled corticosteroids.
    explanation: The guideline update underscores the role of ICS in managing stable COPD, highlighting their long-term use for reducing symptoms and managing exacerbations.
  - reference: PMID:30846476
    reference_title: "Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease: the GOLD science committee report 2019."
    supports: SUPPORT
    snippet: Recent large randomised controlled trials have provided important new information concerning the therapeutic effects of ICSs and long-acting bronchodilators on exacerbations.
    explanation: The new evidence indicates that ICS are effective in reducing exacerbations, supporting their role in treatment.
  treatment_term:
    preferred_term: respiratory tract agent therapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
- name: Phosphodiesterase-4 Inhibitors
  description: Reduce inflammation and relax airways.
  evidence:
  - reference: PMID:15699784
    reference_title: "Selective phosphodiesterase-4 inhibitors in chronic obstructive lung disease."
    supports: SUPPORT
    snippet: Some of the selective PDE4 inhibitors have demonstrated in vitro and in vivo anti-inflammatory activity on cells commonly linked to airway inflammation in COPD, such as neutrophils.
    explanation: The reference indicates that selective phosphodiesterase 4 inhibitors show anti-inflammatory activity, supporting the statement about reducing inflammation.
  - reference: PMID:20649375
    reference_title: "Roflumilast for the treatment of chronic obstructive pulmonary disease."
    supports: SUPPORT
    snippet: Roflumilast targets inflammatory processes in COPD, with beneficial effects on tobacco-induced lung inflammation, lung fibrosis and remodeling, mucociliary malfunction and oxidative stress.
    explanation: Roflumilast, a PDE4 inhibitor, targets inflammatory processes, thus supporting the statement.
  - reference: PMID:34731461
    reference_title: "Inhaled Phosphodiesterase Inhibitors for the Treatment of Chronic Obstructive Pulmonary Disease."
    supports: SUPPORT
    snippet: The orally administered PDE4 inhibitor roflumilast reduces exacerbation rates in the subgroup of chronic obstructive pulmonary disease patients with a history of exacerbations and the presence of chronic bronchitis, but can cause PDE4 related adverse effects due to systemic exposure.
    explanation: This reference confirms the anti-inflammatory effect of PDE4 inhibitors which aligns with the statement.
  - reference: PMID:32361678
    reference_title: "Kinase inhibitors in the treatment of obstructive pulmonary diseases."
    supports: SUPPORT
    snippet: Protein kinases have been implicated in mediating inflammatory signals and airway remodeling associated with reduced lung function in chronic pulmonary disease.
    explanation: This reference supports the role of PDE inhibitors, specifically kinase inhibitors, in reducing inflammation in COPD.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
- name: Oxygen Therapy
  description: Long-term oxygen use for patients with severe chronic hypoxemia.
  evidence:
  - reference: PMID:24461631
    reference_title: "Continuous home oxygen therapy."
    supports: SUPPORT
    snippet: This therapeutic intervention has been shown to increase survival in patients with chronic obstructive pulmonary disease (COPD) and respiratory failure.
    explanation: The literature supports that long-term oxygen therapy (LTOT) is used to treat patients with COPD who have severe chronic hypoxemia.
  - reference: PMID:37353334
    reference_title: "Oxygen Therapy in COPD."
    supports: SUPPORT
    snippet: Long-term oxygen therapy (LTOT) is a mainstay treatment for patients with severe resting hypoxemia secondary to chronic respiratory conditions including COPD.
    explanation: This reference specifically mentions LTOT as a primary treatment for patients with severe chronic hypoxemia due to COPD.
  - reference: PMID:19462352
    reference_title: "End stage chronic obstructive pulmonary disease."
    supports: SUPPORT
    snippet: Only smoking cessation and long term oxygen therapy (LTOT) improve survival in COPD.
    explanation: This study confirms that LTOT is a treatment that improves survival in patients with severe COPD and chronic hypoxemia.
  treatment_term:
    preferred_term: Oxygen Therapy
    term:
      id: NCIT:C94624
      label: Oxygen Therapy
- name: Pulmonary Rehabilitation
  description: Exercise training, education, and support to improve quality of life and physical conditioning.
  evidence:
  - reference: PMID:29526182
    reference_title: "Pulmonary Rehabilitation and Exercise Training in Chronic Obstructive Pulmonary Disease."
    supports: SUPPORT
    snippet: PR is an effective and cost-effective therapeutic intervention that improves physical performance ability, shortness of breath, and the quality of life in patients with COPD.
    explanation: The reference indicates that pulmonary rehabilitation (PR) improves physical performance, shortness of breath, and quality of life in COPD patients, aligning with the statement's description of treatments including exercise training, education, and support.
  - reference: PMID:34338012
    reference_title: "Management of chronic obstructive pulmonary disease."
    supports: SUPPORT
    snippet: Exercise improves the physiological and psychological condition of people with chronic obstructive pulmonary disease and should be encouraged, with referral to a pulmonary rehabilitation service if available.
    explanation: This reference supports the statement's claim by emphasizing the importance of exercise and recommending pulmonary rehabilitation to improve the quality of life and physical conditioning in COPD patients.
  - reference: PMID:34955635
    reference_title: "Self-Efficacy Intervention Programs in Patients with Chronic Obstructive Pulmonary Disease: Narrative Review."
    supports: SUPPORT
    snippet: The combination of drug therapy with non-drug therapy such as pulmonary rehabilitation training has demonstrated a great potential in reducing the occurrence of complications and delaying the progression of COPD.
    explanation: This reference supports the statement by highlighting the benefits of pulmonary rehabilitation training, specifically its potential to improve quality of life and physical conditioning in COPD patients.
  - reference: PMID:24874124
    reference_title: "The systemic nature of chronic lung disease."
    supports: SUPPORT
    snippet: Pulmonary rehabilitation targets the systemic manifestations of COPD, the causes of which include inactivity, systemic inflammation, hypoxia and corticosteroid treatment.
    explanation: This reference supports the statement by indicating that pulmonary rehabilitation addresses systemic issues in COPD and implies improvement in quality of life and physical conditioning.
  - reference: PMID:24507849
    reference_title: "Pulmonary rehabilitation."
    supports: SUPPORT
    snippet: The main objective of pulmonary rehabilitation is to restore muscle function and exercise tolerance, reverse other nonrespiratory consequences of the disease, and help patients to self-manage chronic obstructive pulmonary disease and its exacerbations and symptoms.
    explanation: This reference supports the statement by detailing the benefits of pulmonary rehabilitation, including exercise training, education, and support, to improve quality of life and physical conditioning.
  therapeutic_modality: BEHAVIORAL
  treatment_term:
    preferred_term: physical therapy
    term:
      id: NCIT:C15302
      label: Physical Therapy
- name: Lung Volume Reduction Surgery
  description: Surgical removal of damaged lung tissue for severe emphysema.
  evidence:
  - reference: PMID:22189668
    reference_title: "Lung volume reduction for advanced emphysema: surgical and bronchoscopic approaches."
    supports: SUPPORT
    snippet: Surgical approaches include lung transplantation and lung volume reduction and the latter has been shown to improve exercise tolerance, quality of life, and survival in highly selected patients with advanced emphysema.
    explanation: The literature supports the use of lung volume reduction surgery as a treatment for severe emphysema in chronic obstructive pulmonary disease (COPD) patients.
  - reference: PMID:33926668
    reference_title: "Alpha(1)-antitrypsin Disease, Treatment and Role for Lung Volume Reduction Surgery."
    supports: SUPPORT
    snippet: As symptoms and lung function decline, treatment modalities, such as lung volume reduction surgery, have been used in individuals with chronic obstructive pulmonary disease and upper lobe predominant emphysema.
    explanation: The literature indicates that lung volume reduction surgery is a treatment used for severe emphysema, a condition associated with COPD.
  - reference: PMID:31145187
    reference_title: "Emerging Interventional Pulmonary Therapies for Chronic Obstructive Pulmonary Disease."
    supports: SUPPORT
    snippet: 'Mortality benefits to therapy have been demonstrated in only 2 therapeutic interventions to date: long-term use of daily supplemental oxygen and surgical lung volume reduction (LVRS) for upper-lobe-predominant disease in patients with a low baseline exercise capacity.'
    explanation: The statement is supported as the literature suggests that lung volume reduction surgery is an established treatment for upper-lobe-predominant, severe emphysema in COPD patients.
  therapeutic_modality: SURGERY
  treatment_term:
    preferred_term: surgical procedure
    term:
      id: NCIT:C15329
      label: Surgical Procedure
- name: Lung Transplantation
  description: Considered in end-stage COPD with severe impairment.
  evidence:
  - reference: PMID:17240617
    reference_title: "Transplantation in chronic obstructive pulmonary disease."
    supports: SUPPORT
    snippet: Lung transplantation is a surgical option for patients who fail optimization of medical treatment for the severe symptoms that result from COPD.
    explanation: This reference states that lung transplantation is a considered treatment option for patients with severe symptoms resulting from COPD.
  - reference: PMID:31375190
    reference_title: "Palliative Care Approach to Chronic Diseases: End Stages of Heart Failure, Chronic Obstructive Pulmonary Disease, Liver Failure, and Renal Failure."
    supports: SUPPORT
    snippet: End-stage congestive heart failure, chronic obstructive pulmonary disease...palliative principles can guide decision making and symptom management in these disease states.
    explanation: The reference focuses on end-stage COPD and mentions lung transplantation as a consideration in managing the conditions of patients.
  - reference: PMID:36050206
    reference_title: "The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Thirty-ninth adult lung transplantation report-2022; focus on lung transplant recipients with chronic obstructive pulmonary disease."
    supports: SUPPORT
    snippet: The International Thoracic Organ Transplant Registry...focus on lung transplant recipients with chronic obstructive pulmonary disease.
    explanation: This source concentrates on lung transplantation for patients with COPD, in line with the statement's context of it being a treatment for end-stage COPD.
  - reference: PMID:23248802
    reference_title: "A brief review of chronic obstructive pulmonary disease."
    supports: SUPPORT
    snippet: Chronic obstructive pulmonary disease...treated by lung transplantation.
    explanation: This abstract explicitly mentions the use of lung transplantation for individuals with very severe COPD.
  therapeutic_modality: SURGERY
  treatment_term:
    preferred_term: organ transplantation
    term:
      id: NCIT:C15289
      label: Organ Transplantation
- name: Mucolytic Therapy
  description: N-acetylcysteine and other mucolytics reduce mucus viscosity and may improve mucociliary clearance.
  notes: Variable clinical impact across COPD phenotypes; targets MUC5AC/MUC5B expression and mucus rheology.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
- name: Macrolide Antibiotics
  description: Long-term macrolide therapy reduces exacerbation frequency but raises antimicrobial resistance concerns.
  notes: Used in chronic bronchitis phenotype; dual anti-inflammatory and antimicrobial effects.
  treatment_term:
    preferred_term: antibiotic therapy
    term:
      id: NCIT:C15620
      label: Antibiotic Therapy
- name: Biologic Therapies
  description: Precision biologics targeting Type 2 inflammation in eosinophilic COPD subsets.
  notes: Dupilumab (anti-IL-4/IL-13) shows benefit in eosinophilic COPD; anti-IL-33 and anti-TSLP under investigation.
  treatment_term:
    preferred_term: biologic therapy
    term:
      id: NCIT:C15262
      label: Immunotherapy
review_notes: COPD is characterized by progressive airflow obstruction that is not fully reversible. Key respiratory symptoms include dyspnea, chronic cough, sputum production, and wheezing. As the disease progresses, patients may develop signs of lung hyperinflation (barrel chest) and are at risk for respiratory failure. Systemic effects like fatigue and weight loss are also common, particularly in advanced disease.
mechanistic_hypotheses:
- hypothesis_group_id: emerging_cuproptosis_metabolic_immune_axis
  hypothesis_label: Emerging Cuproptosis Metabolic-Immune Cell Death Axis
  status: EMERGING
  description: >-
    A 2026 review proposes that cuproptosis — copper-dependent regulated cell
    death driven by mitochondrial proteotoxic stress — is not a bystander
    consequence of COPD but an amplifier of it, running as a self-sustaining
    loop: smoke-induced disruption of pulmonary copper homeostasis permits
    cuproptotic death of alveolar epithelium and M2 macrophages, the resulting
    DAMP release drives neutrophilic inflammation, and that inflammation
    further impairs copper handling in surviving cells. The grouping exists to
    keep the two edges of this loop distinguishable in the pathograph from the
    entry's established protease/antiprotease and oxidative-stress mechanisms.
    Its central vulnerability claim — that OXPHOS-dependent cells are the
    preferential targets — is stated by the authors as a prediction, and the
    review is a synthesis rather than a report of primary human COPD data.
  evidence:
  - reference: PMID:42604614
    reference_title: "Cuproptosis: The metabolic-immune axis in chronic obstructive pulmonary disease pathogenesis and therapeutics."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      In this review, we advance the hypothesis that cuproptosis functions not
      merely as a passive consequence but as a critical amplifier within a
      self-sustaining "Metabolic-Immune Cell Death Axis" that drives disease
      chronicity and progression.
    explanation: >-
      The authors frame the axis as a hypothesis in their own words, which is
      what fixes this grouping's status as EMERGING rather than CANONICAL.
  - reference: PMID:42604614
    reference_title: "Cuproptosis: The metabolic-immune axis in chronic obstructive pulmonary disease pathogenesis and therapeutics."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: while explicitly distinguishing established evidence from speculative hypotheses
    explanation: >-
      Carried deliberately: the review itself marks part of its content as
      speculative, which bounds how far the edges in this group can be read.
  notes: >-
    Contrast with the entry's other cell-death and inflammation nodes, which
    rest on primary human airway data. No competing hypothesis grouping is
    declared, because the established mechanisms in this entry are not framed
    as alternatives to this one — the axis is proposed as superimposed on them.
discussions:
- discussion_id: gap_copd_sirt1_senescence_neutrophilic_translation
  prompt: >-
    Does restoring NAD+-dependent SIRT1 deacetylase activity causally reduce
    neutrophilic airway inflammation and alveolar epithelial senescence in COPD,
    and can SIRT1 activators overcome their pharmacokinetic limitations and be
    paired with biomarker-guided patient stratification to translate this
    protection into therapy?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - pathophysiology#Chronic Inflammation
  - pathophysiology#Cellular Senescence
  rationale: >-
    SIRT1 is reported to protect against COPD by inhibiting NF-kB and STAT3,
    activating Nrf2 and FOXO3, and suppressing TGF-beta/Smad, thereby reducing
    neutrophilic inflammation, mitigating alveolar epithelial senescence, and
    helping restore protease/antiprotease balance. These protective effects are
    mechanistically distinct from SIRT1's role in asthma, where it chiefly
    attenuates type 2 inflammation and mucus hypersecretion, so the disease
    context appears to determine which downstream program SIRT1 restrains. The
    COPD entry captures chronic neutrophilic inflammation and cellular senescence
    as separate nodes but does not resolve whether SIRT1 activity is causally
    required to limit each one, nor in which cell type (alveolar epithelium,
    neutrophil, macrophage) the protective signaling resides. Translation is
    further limited by the poor pharmacokinetics of current SIRT1 activators and
    by the absence of biomarkers to select responders. Resolving the
    cell-type-specific basis of these context-dependent effects and the
    pharmacokinetic and stratification barriers would convert SIRT1 from a
    broadly cytoprotective pathway into a stratified COPD therapeutic target.
  notes: "Seeded from PMID:42181267 — Emerging role of SIRT1 in asthma and COPD from molecular mechanisms to translational therapy"
- discussion_id: gap_copd_cuproptosis_direct_human_evidence
  prompt: >-
    Does cuproptosis actually occur in human COPD airway tissue, and are
    OXPHOS-dependent cells (alveolar type II epithelium, M2 macrophages) the
    preferentially vulnerable populations the metabolic-immune axis model
    predicts?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - pathophysiology#Cuproptosis-Driven Cell Death
  rationale: >-
    The entire cuproptosis node in this entry rests on one review, and that
    review's own roadmap puts direct human evidence first among what is
    missing. The cell-type vulnerability claim is stated as a prediction from
    metabolic dependency rather than as an observation, so the node's cell-type
    bindings (CL:0002063, CL:0000890) record what the model expects rather than
    what has been measured in patient tissue. Resolving this would need
    demonstration of the cuproptosis signature — copper-dependent aggregation
    of lipoylated mitochondrial proteins and Fe-S cluster loss — in COPD lung
    with the affected cells identified, which would move the
    emerging_cuproptosis_metabolic_immune_axis grouping toward established
    status or refute it. The related therapeutic question is separately
    blocked: every proposed copper chelator, ionophore, nanoplatform and
    PROTAC sensitizer is preclinical, so none is curated under treatments.
  evidence:
  - reference: PMID:42604614
    reference_title: "Cuproptosis: The metabolic-immune axis in chronic obstructive pulmonary disease pathogenesis and therapeutics."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: prioritizing direct human evidence, biomarker validation, and rigorous preclinical safety studies
    explanation: >-
      The review's own research roadmap names direct human evidence as the
      first outstanding requirement, which is the gap this entry records.
  - reference: PMID:42604614
    reference_title: "Cuproptosis: The metabolic-immune axis in chronic obstructive pulmonary disease pathogenesis and therapeutics."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: we emphasize that all these approaches remain at preclinical or early exploratory stages, with no clinical trials yet conducted in COPD
    explanation: >-
      Establishes why the surveyed copper-directed therapeutics are recorded
      here rather than curated as treatments.
  notes: >-
    Seeded from PMID:42604614 alongside the cuproptosis node added in #10119.
disease_term:
  preferred_term: chronic obstructive pulmonary disease
  term:
    id: MONDO:0005002
    label: chronic obstructive pulmonary disease
classifications:
  harrisons_chapter:
  - classification_value: RESPIRATORY
references:
- reference: DOI:10.1136/thorax-2023-220455
  title: Lower airway microbiota in COPD and healthy controls
  findings: []
- reference: DOI:10.1164/rccm.202306-1060oc
  title: Accelerated Lung Function Decline and Mucus–Microbe Evolution in Chronic Obstructive Pulmonary Disease
  findings: []
- reference: DOI:10.1183/23120541.00177-2024
  title: What every clinician should know about inflammation in COPD
  findings: []
- reference: DOI:10.3389/fimmu.2024.1404615
  title: Inflammation mechanism and research progress of COPD
  findings: []
- reference: DOI:10.3390/ijms25147780
  title: Cellular and Molecular Biology of Mitochondria in Chronic Obstructive Pulmonary Disease
  findings: []
- reference: DOI:10.3390/ijms26052184
  title: 'Molecular Approaches to Treating Chronic Obstructive Pulmonary Disease: Current Perspectives and Future Directions'
  findings: []
datasets:
- accession: geo:GSE324136
  title: Integrative multi-omic analyses identify major axes of heterogeneity in chronic obstructive pulmonary disease and uncover their molecular contributors - ECLIPSE replication cohort
  description: Chronic Obstructive Pulmonary Disease (COPD) is a complex, heterogeneous disease. Traditional subtyping methods generally focus on either the clinical manifestations or the molecular endotypes of the disease, leading to classifications that only partially reflect disease heterogeneity. Here, we introduce a variational autoencoder-based subtyping pipeline that jointly embeds clinical and gene expression data into a single subject-level representation. We evaluate the framework in the COPDGene study, a large study of current and former smoking individuals with and without COPD.
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  data_type: MICROARRAY
  sample_count: 628
  notes: Identified by GEO DataSets index search for Chronic Obstructive Pulmonary Disease (scripts/discover_datasets.py); accession and metadata verified against NCBI E-utilities on 2026-07-31. Title, sample count, and organism are GEO's own values.
- accession: ega:EGAS00001006398
  title: Multi-omics analyses of airway host-microbe interactions in chronic obstructive pulmonary disease identify potential therapeutic interventions
  description: The mechanistic role of the airway microbiome in chronic obstructive pulmonary disease (COPD) remains largely unexplored. We present a landscape of airway microbe-host interactions in COPD through an in-depth profiling of the sputum metagenome, metabolome, host transcriptome and proteome from 99 COPD patients and 36 healthy individuals in China.
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  notes: 'European Genome-phenome Archive study, matched because the disease is named in the study''s own title ("Chronic Obstructive Pulmonary Disease"); description-level mentions were not accepted. EGA study_type: Other. Controlled access -- data require a Data Access Agreement. EGA metadata retrieved 2026-08-01.'
- accession: ega:EGAS00001006444
  title: Airway Dysbiosis Accelerates Lung Function Decline in Chronic Obstructive Pulmonary Disease
  description: This repository contains human sample derived microbiome full-length 16S rRNA sequencing data for sputum samples in COPD patients. The project goal is to understand the association of the lung microbiome with accelerated lung function decline in COPD patients.
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  notes: 'European Genome-phenome Archive study, matched because the disease is named in the study''s own title ("Chronic Obstructive Pulmonary Disease"); description-level mentions were not accepted. EGA study_type: Other. Controlled access -- data require a Data Access Agreement. EGA metadata retrieved 2026-08-01.'

experimental_models:
- name: Open-top vascularized alveolus-on-chip whole cigarette smoke model
  description: >-
    A membrane-free, open-top alveolus-on-chip in which primary human lung
    endothelial cells and pericytes self-assemble into a perfusable
    three-dimensional microvascular network, with alveolar type 2 epithelial
    cells cultured directly on the vascularized hydrogel. The open top permits
    exposure to whole cigarette smoke rather than to smoke extract, so the
    exposure is airborne and confined to the epithelial surface.
  experimental_model_type: ORGAN_ON_CHIP
  namo_type: namo:OrganOnChip
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  tissue_term:
    preferred_term: alveolus of lung
    term:
      id: UBERON:0002299
      label: alveolus of lung
  cell_types:
  - preferred_term: Pulmonary alveolar type 2 cell
    term:
      id: CL:0002063
      label: pulmonary alveolar type 2 cell
  - preferred_term: Pulmonary capillary endothelial cell
    term:
      id: CL:4028001
      label: pulmonary capillary endothelial cell
  - preferred_term: Pericyte
    term:
      id: CL:0000669
      label: pericyte
  conditions:
  - repeated whole cigarette smoke exposure
  - air-exposed control
  - endothelial network without alveolar epithelium
  cell_source: Primary human lung endothelial cells, pericytes, and alveolar type 2 cells, including
    cells from stage II and stage IV COPD patients
  culture_system: Open-top membrane-free microfluidic chip with self-assembled perfusable vascular network
  publication: PMID:42473541
  modeled_mechanisms:
  - target: Alveolar Destruction
    relationship: PARTIALLY_RECAPITULATES
    fidelity: MODERATE
    description: >-
      Repeated whole cigarette smoke exposure disintegrated the alveolar
      microvascular network. The informative control is that the epithelium
      itself stayed intact and that vascular networks exposed to smoke without an
      overlying epithelium were undamaged, which locates the vascular injury
      downstream of an epithelial signal rather than in direct smoke contact.
      This supports the vascular limb of the alveolar destruction in emphysema.
    limitations: >-
      The AEC2-dependence experiment rests on two donors and is described by the
      authors as preliminary; the mediating epithelial factors are unidentified.
      The model also captures capillary loss over days rather than the airspace
      enlargement and elastin degradation that define emphysema over decades, and
      it has no infiltrating leukocytes.
    readouts:
    - name: Integrity of the alveolar endothelial-pericyte vascular network
      target: Alveolar Destruction
      direction: DECREASED
      interpretation: >-
        Loss of continuous CD31-positive vessels after smoke exposure is the
        microvascular correlate of alveolar destruction.
      evidence:
      - reference: PMID:42473541
        reference_title: Modelling cigarette smoke-induced lung vascular dysfunction using an alveolus-on-chip.
        supports: SUPPORT
        evidence_source: IN_VITRO
        snippet: Importantly, exposure of the AEC2 layer to whole cigarette smoke (WCS) led to disintegration
          of the underlying vascular network, an effect not observed in the absence of AEC2.
        explanation: Reports both the vascular disintegration and the epithelium-dependence control.
    - name: Alveolar epithelial monolayer morphology after smoke exposure
      target: Alveolar Destruction
      direction: UNCHANGED
      interpretation: >-
        The directly exposed epithelium was preserved while the unexposed
        endothelium failed, a negative result that reverses the expected order of
        susceptibility.
      evidence:
      - reference: PMID:42473541
        reference_title: Modelling cigarette smoke-induced lung vascular dysfunction using an alveolus-on-chip.
        supports: SUPPORT
        evidence_source: IN_VITRO
        snippet: Here, we demonstrated that endothelial cells were more susceptible to cigarette smoke
          exposure compared to AEC2 as vascular networks disintegrated while the alveolar epithelium remained
          intact.
        explanation: Documents the preserved epithelium alongside the failed endothelium.
    evidence:
    - reference: PMID:42473541
      reference_title: Modelling cigarette smoke-induced lung vascular dysfunction using an alveolus-on-chip.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: These data are however still preliminary and need further repetition and expansion to identify
        AEC2-derived factors involved in the disintegration of the vascular networks upon smoke exposure.
      explanation: The authors' own statement that the epithelium-mediated mechanism is preliminary;
        PARTIAL records the model as informative but not yet established for this node.
  - target: Oxidative Stress and Mitochondrial Dysfunction
    relationship: MEASURES
    fidelity: LOW
    description: >-
      The platform delivers a controlled, repeated airborne whole-smoke exposure
      to human alveolar cells and supports perfusion of monocytes through the
      vascular network, providing a route to measure smoke-induced injury and
      immune recruitment together.
    limitations: >-
      This study reported structural and gene-expression endpoints rather than
      direct measurements of reactive oxygen species or mitochondrial function,
      so support for this node is by exposure relevance rather than by a matching
      readout.
    evidence:
    - reference: PMID:42473541
      reference_title: Modelling cigarette smoke-induced lung vascular dysfunction using an alveolus-on-chip.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: Of note, we also confirmed that pulmonary endothelial cells isolated from two different
        COPD patients (stage II and stage IV) were able to form vascular networks
      explanation: Establishes that patient-derived COPD endothelium can be used in the platform,
        supporting disease relevance; PARTIAL because no oxidative-stress readout was reported.
- name: Patient-derived epithelial-endothelial COPD airway-on-a-chip
  description: >-
    A perfused airway-on-a-chip pairing primary airway epithelial cells with
    pulmonary microvascular endothelial cells under air-liquid interface, built
    in matched healthy-donor and COPD-patient versions so the two can be compared
    under identical culture conditions. Using patient-derived cells on both sides
    of the barrier preserves the donor's disease phenotype rather than inducing
    one with an exposure.
  experimental_model_type: ORGAN_ON_CHIP
  namo_type: namo:OrganOnChip
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  tissue_term:
    preferred_term: epithelium of bronchus
    term:
      id: UBERON:0002031
      label: epithelium of bronchus
  cell_types:
  - preferred_term: Bronchial epithelial cell
    term:
      id: CL:0002328
      label: bronchial epithelial cell
  - preferred_term: Pulmonary capillary endothelial cell
    term:
      id: CL:4028001
      label: pulmonary capillary endothelial cell
  conditions:
  - COPD patient-derived cells
  - healthy donor control
  cell_source: Primary airway epithelial and pulmonary microvascular endothelial cells from COPD patients
    and healthy donors
  culture_system: Perfused microfluidic airway-on-a-chip at air-liquid interface
  publication: PMID:42475431
  modeled_mechanisms:
  - target: Mucus Hypersecretion
    relationship: RECAPITULATES
    fidelity: MODERATE
    description: >-
      Chips built from COPD patient cells showed enhanced mucus production
      relative to healthy-donor chips under identical conditions, reproducing a
      cardinal COPD phenotype without any exposure being applied.
    limitations: >-
      The mucus phenotype appeared without the loss of barrier function or cell
      viability seen in advanced disease, so the model represents the secretory
      abnormality in isolation. Donor numbers are small and the protocol is
      published as a methods article rather than a powered comparative study.
    readouts:
    - name: Mucus production in COPD-derived versus healthy-donor chips
      target: Mucus Hypersecretion
      direction: INCREASED
      interpretation: >-
        Increased mucus in patient-derived epithelium under identical conditions
        attributes the phenotype to the cells rather than to the exposure.
      evidence:
      - reference: PMID:42475431
        reference_title: Establishing An Epithelial-Endothelial Co-Culture Lung-on-a-chip For Investigation
          In Healthy and COPD Conditions.
        supports: SUPPORT
        evidence_source: IN_VITRO
        snippet: The COPD model recapitulated key features of the disease, notably enhanced mucus production,
          without compromising barrier function or cell viability.
        explanation: Reports the mucus phenotype and its limits in the same sentence.
    evidence:
    - reference: PMID:42475431
      reference_title: Establishing An Epithelial-Endothelial Co-Culture Lung-on-a-chip For Investigation
        In Healthy and COPD Conditions.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: The use of patient-derived epithelial and endothelial cells preserves individual pathological
        characteristics, enabling investigation of intercellular mechanisms in COPD.
      explanation: Supports the patient-derived chip as carrying genuine COPD phenotype into the model.
  - target: Airway Remodeling
    relationship: MEASURES
    fidelity: LOW
    description: >-
      The chip supports full mucociliary differentiation with ciliary beating and
      permits compartment-specific RNA extraction, giving a route to measure
      epithelial differentiation state and epithelial-endothelial crosstalk in
      COPD cells.
    limitations: >-
      Barrier integrity and junctional localization were preserved in the COPD
      chips, so the model does not reproduce the structural remodelling —
      subepithelial fibrosis, smooth muscle thickening, squamous metaplasia —
      that this node describes. It is a platform for measuring remodelling
      signals, not a model of the remodelled airway.
    evidence:
    - reference: PMID:42475431
      reference_title: Establishing An Epithelial-Endothelial Co-Culture Lung-on-a-chip For Investigation
        In Healthy and COPD Conditions.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: Permeability assays demonstrated robust barrier integrity in both systems, while immunofluorescence
        confirmed continuous localization of Zonula Occludens-1 (ZO-1) and vascular endothelial cadherin
        (VE-cadherin) at cell junctions.
      explanation: Preserved barrier and junctions in both healthy and COPD chips bound what this model
        can say about remodelling; PARTIAL reflects that limit.

📚

References & Deep Research